Document:

exv10w3

REGISTRATION RIGHTS AGREEMENT

          This Registration Rights Agreement (this “Agreement”) is made and entered into as of
November 20, 2008, by and among Escalon Medical Corp., a Pennsylvania corporation (the
“Company”), and the purchasers signatory hereto (each such purchaser, a “Purchaser”
and collectively, the “Purchasers”).

          This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date
hereof among the Company and the Purchasers (the “Purchase Agreement”)

          The Company and the Purchasers hereby agree as follows:

     1. Definitions. Capitalized terms used and not otherwise defined herein that are
defined in the Purchase Agreement shall have the meanings given such terms in the Purchase
Agreement. As used in this Agreement, the following terms shall have the following meanings:

     “Advice” shall have the meaning set forth in Section 6(d).

     “Effectiveness Date” means, with respect to the Registration Statement required
to be filed hereunder, the earlier of (a) the 75th calendar day following the
date of the Purchase Agreement, unless the Commission conducts a full review of the
Registration Statement, in which case the 120th calendar day shall apply to this
clause (a) rather than the 75th calendar day, and (b) the fifth Trading Day
following the date on which the Company is notified by the Commission that the Registration
Statement will not be reviewed or is no longer subject to further review and comments.

     “Effectiveness Period” shall have the meaning set forth in Section 2.

     “Filing Date” means, with respect to the Registration Statement required to be
filed hereunder, the 30th calendar day following the date of the Purchase
Agreement.

     “Holder” or “Holders” means the holder or holders, as the case may be,
from time to time of Registrable Securities.

     “Indemnified Party” shall have the meaning set forth in Section 5(c).

     “Indemnifying Party” shall have the meaning set forth in Section 5(c).

     “Losses” shall have the meaning set forth in Section 5(a).

     “Proceeding” means an action, claim, suit, investigation or proceeding
(including, without limitation, an investigation or partial proceeding, such as a
deposition), whether commenced or threatened.

     “Prospectus” means the prospectus included in the Registration Statement
(including, without limitation, a prospectus that includes any information previously
omitted from a prospectus filed as part of an effective registration statement in reliance

-1-

 

upon Rule 430A promulgated under the Securities Act), as amended or supplemented by any
prospectus supplement, with respect to the terms of the offering of any portion of the
Registrable Securities covered by the Registration Statement, and all other amendments and
supplements to the Prospectus, including post-effective amendments, and all material
incorporated by reference or deemed to be incorporated by reference in such Prospectus.

     “Registrable Securities” means all of the Shares, together with any shares of
Common Stock issued or issuable upon any stock split, dividend or other distribution,
recapitalization or similar event with respect to the foregoing, and the Warrant Shares.

     “Registration Statement” means the registration statements required to be filed
hereunder, including (in each case) the Prospectus, amendments and supplements to the
registration statement or Prospectus, including pre- and post-effective amendments, all
exhibits thereto, and all material incorporated by reference or deemed to be incorporated by
reference in the registration statement.

     “Rule 415” means Rule 415 promulgated by the Commission pursuant to the
Securities Act, as such Rule may be amended from time to time, or any similar rule or
regulation hereafter adopted by the Commission having substantially the same purpose and
effect as such Rule.

     “Rule 424” means Rule 424 promulgated by the Commission pursuant to the
Securities Act, as such Rule may be amended from time to time, or any similar rule or
regulation hereafter adopted by the Commission having substantially the same purpose and
effect as such Rule.

     2. Registration. On or prior to the Filing Date, the Company shall prepare and file
with the Commission the Registration Statement covering the resale of all of the Registrable
Securities for an offering to be made on a continuous basis pursuant to Rule 415. The Registration
Statement required hereunder shall be on Form S-3 (except if the Company is not then eligible to
register for resale the Registrable Securities on Form S-3, in which case the Registration shall be
on another appropriate form permitting registration of the Registrable Securities for resale by
such Holders in accordance herewith and the methods of distribution elected by the Holders herein).
The Registration Statement required hereunder shall contain (except if otherwise directed by the
Holders) substantially the “Plan of Distribution” attached hereto as Annex A.
Subject to the terms of this Agreement, the Company shall use best efforts to cause the
Registration Statement to be declared effective under the Securities Act as promptly as possible
after the filing thereof, but in any event not later than the Effectiveness Date, and shall use
best efforts to keep the Registration Statement continuously effective under the Securities Act
until the date when all Registrable Securities covered by the Registration Statement have been sold
or may be sold without registration under the Securities Act pursuant to the final sentence of Rule
144(b)(1)(i) as determined by the counsel to the Company pursuant to a written opinion letter to
such effect, addressed and acceptable to the Company’s transfer agent and the affected Holders (the
“Effectiveness Period”). None of the Company’s security holders (other than the Holders of
Registrable Securities) shall have the right to include any of the Company’s securities in the
Registration Statement to be filed pursuant to this Section 2.

-2-

 

     3. Registration Procedures

          In connection with the Company’s registration obligations hereunder, the Company shall:

     (a) Furnish to the Holders copies of all such documents filed (including documents
incorporated or deemed incorporated by reference to the extent requested by such Holder),
not more than five Trading Days after the filing of the Registration Statement or any
related Prospectus or any amendment or supplement thereto.

     (b) (i) Prepare and file with the Commission such amendments, including post-effective
amendments, to the Registration Statement and the Prospectus used in connection therewith as
may be necessary to keep the Registration Statement continuously effective as to the
applicable Registrable Securities for the Effectiveness Period; (ii) cause the related
Prospectus to be amended or supplemented by any required Prospectus supplement, and as so
supplemented or amended to be filed pursuant to Rule 424; (iii) respond as promptly as
reasonably possible to any comments received from the Commission with respect to the
Registration Statement or any amendment thereto; and (iv) comply in all material respects
with the provisions of the Securities Act and the Exchange Act with respect to the
disposition of all Registrable Securities covered by the Registration Statement during the
Effectiveness Period in accordance with the intended methods of disposition by the Holders
thereof set forth in the Registration Statement as so amended or in such Prospectus as so
supplemented.

     (c) Notify the Holders of Registrable Securities to be sold as promptly as reasonably
possible and (if requested by any such Holder) confirm such notice in writing promptly
following the day (i)(A) when the Registration Statement and Prospectus or any Prospectus
supplement or post-effective amendment to the Registration Statement is filed; (B) when the
Commission notifies the Company whether there will be a “review” of the Registration
Statement and whenever the Commission comments in writing on the Registration Statement; and
(C) with respect to the Registration Statement or any post-effective amendment, when the
same has become effective; (ii) of any request by the Commission or any other Federal or
state governmental authority during the Effectiveness Period for amendments or supplements
to the Registration Statement or Prospectus or for additional information; (iii) of the
issuance by the Commission or any other Federal or state governmental authority of any stop
order suspending the effectiveness of the Registration Statement covering any or all of the
Registrable Securities or the initiation of any Proceedings for that purpose; (iv) of the
receipt by the Company of any notification with respect to the suspension of the
qualification or exemption from qualification of any of the Registrable Securities for sale
in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose;
and (v) of the occurrence of any event or passage of time that makes the financial
statements included in the Registration Statement ineligible for inclusion therein or any
statement made in the Registration Statement or Prospectus or any document incorporated or
deemed to be incorporated therein by reference untrue in any material respect or that
requires any revisions to the Registration Statement, Prospectus or other documents so that,
in the case of the Registration Statement, Prospectus or other documents, as the case

-3-

 

may be, it will not contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the statements therein,
in light of the circumstances under which they were made, not misleading.

     (d) Use reasonable efforts to avoid the issuance of, or, if issued, obtain the
withdrawal of (i) any order suspending the effectiveness of the Registration Statement, or
(ii) any suspension of the qualification (or exemption from qualification) of any of the
Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.

     (e) Furnish to each Holder, without charge, at least one conformed copy of the
Registration Statement and each amendment thereto, including financial statements and
schedules, all documents incorporated or deemed to be incorporated therein by reference to
the extent requested by such Person, and all exhibits to the extent requested by such Person
(including those previously furnished or incorporated by reference) promptly after the
filing of such documents with the Commission.

     (f) Promptly deliver to each Holder, without charge, as many copies of the Prospectus
or Prospectuses (including each form of prospectus) and each amendment or supplement thereto
as such Holder may reasonably request in connection with resales by the Holder of
Registrable Securities. Subject to the terms of this Agreement, the Company hereby consents
to the use of such Prospectus and each amendment or supplement thereto by each of the
selling Holders in connection with the offering and sale of the Registrable Securities
covered by such Prospectus and any amendment or supplement thereto, except after the giving
of any notice pursuant to Section 3(c)(ii), (iii), (iv) or (v).

     (g) Prior to any resale of Registrable Securities by a Holder, use its reasonable
efforts to register or qualify or cooperate with the selling Holders in connection with the
registration or qualification (or exemption from the registration or qualification) of such
Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of
such jurisdictions within the United States as any Holder reasonably requests in writing, to
keep the registration or qualification (or exemption therefrom) effective during the
Effectiveness Period and to do any and all other acts or things reasonably necessary to
enable the disposition in such jurisdictions of the Registrable Securities covered by the
Registration Statement; provided, that the Company shall not be required to qualify
generally to do business in any jurisdiction where it is not then so qualified, subject the
Company to any material tax in any such jurisdiction where it is not then so subject or file
a general consent to service of process in any such jurisdiction.

     (h) If requested by the Holders, cooperate with the Holders to facilitate the timely
preparation and delivery of certificates representing Registrable Securities to be delivered
to a transferee pursuant to the Registration Statement, which certificates shall be free, to
the extent permitted by the Purchase Agreement, of all restrictive legends, and to enable
such Registrable Securities to be in such denominations and registered in such names as any
such Holders may request.

-4-

 

     (i) Upon the occurrence of any event contemplated by Section 3(c)(v), as promptly and
in any event within 30 days of such event, prepare a supplement or amendment, including a
post-effective amendment, to the Registration Statement or a supplement to the related
Prospectus or any document incorporated or deemed to be incorporated therein by reference,
and file any other required document so that, as thereafter delivered, neither the
Registration Statement nor such Prospectus will contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made, not
misleading. If the Company notifies the Holders in accordance with clauses (ii) through (v)
of Section 3(c) above to suspend the use of any Prospectus until the requisite changes to
such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The
Company will use reasonable efforts to ensure that the use of the Prospectus may be resumed
as promptly as is practicable.

     (j) Comply with all applicable rules and regulations of the Commission.

     (k) The Company may require each selling Holder to furnish to the Company a certified
statement as to the number of shares of Common Stock beneficially owned by such Holder and,
if required by the Commission, the person thereof that has voting and dispositive control
over the Shares.

     4. Registration Expenses. All fees and expenses incident to the performance of or
compliance with this Agreement by the Company shall be borne by the Company whether or not any
Registrable Securities are sold pursuant to the Registration Statement. The fees and expenses
referred to in the foregoing sentence shall include, without limitation, (i) all registration and
filing fees (including, without limitation, fees and expenses (A) with respect to filings required
to be made with the Principal Market on which the Common Stock is then listed for trading, and (B)
in compliance with applicable state securities or Blue Sky laws), (ii) printing expenses
(including, without limitation, expenses of printing certificates for Registrable Securities and of
printing prospectuses if the printing of prospectuses is reasonably requested by the holders of a
majority of the Registrable Securities included in the Registration Statement), (iii) messenger,
telephone and delivery expenses, (iv) reasonable fees and disbursements of counsel for the Company
and the Holders, (v) Securities Act liability insurance, if the Company so desires such insurance,
and (vi) fees and expenses of all other Persons retained by the Company in connection with the
consummation of the transactions contemplated by this Agreement. In addition, the Company shall be
responsible for all of its internal expenses incurred in connection with the consummation of the
transactions contemplated by this Agreement (including, without limitation, all salaries and
expenses of its officers and employees performing legal or accounting duties), the expense of any
annual audit and the fees and expenses incurred in connection with the listing of the Registrable
Securities on any securities exchange as required hereunder. In no event shall the Company be
responsible for any broker or similar commissions or, except to the extent provided for in the
Transaction Documents, any legal fees or other costs of the Holders.

-5-

 

     5. Indemnification

     (a) Indemnification by the Company. The Company shall, notwithstanding any
termination of this Agreement, indemnify and hold harmless each Holder, the officers,
directors, agents and employees of each of them, each Person who controls any such Holder
(within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act)
and the officers, directors, agents and employees of each such controlling Person, to the
fullest extent permitted by applicable law, from and against any and all losses, claims,
damages, liabilities, costs (including, without limitation, reasonable attorneys’ fees) and
expenses (collectively, “Losses”), as incurred, arising out of or relating to any
untrue or alleged untrue statement of a material fact contained in the Registration
Statement, any Prospectus or any form of prospectus or in any amendment or supplement
thereto or in any preliminary prospectus, or arising out of or relating to any omission or
alleged omission of a material fact required to be stated therein or necessary to make the
statements therein (in the case of any Prospectus or form of prospectus or supplement
thereto, in light of the circumstances under which they were made) not misleading, except to
the extent, but only to the extent, that (i) such untrue statements or omissions are based
solely upon information regarding such Holder furnished in writing to the Company by such
Holder expressly for use therein, or to the extent that such information relates to such
Holder or such Holder’s proposed method of distribution of Registrable Securities and was
reviewed and expressly approved in writing by such Holder expressly for use in the
Registration Statement, such Prospectus or such form of Prospectus or in any amendment or
supplement thereto (it being understood that the Holder has approved Annex A hereto for this
purpose) or (ii) in the case of an occurrence of an event of the type specified in Section
3(c)(ii)-(v), the use by such Holder of an outdated or defective Prospectus after the
Company has notified such Holder in writing that the Prospectus is outdated or defective and
prior to the receipt by such Holder of the Advice contemplated in Section 6(d). The Company
shall notify the Holders promptly of the institution, threat or assertion of any Proceeding
of which the Company is aware in connection with the transactions contemplated by this
Agreement.

     (b) Indemnification by Holders. Each Holder shall, severally and not jointly,
indemnify and hold harmless the Company, its directors, officers, agents and employees, each
Person who controls the Company (within the meaning of Section 15 of the Securities Act and
Section 20 of the Exchange Act), and the directors, officers, agents or employees of such
controlling Persons, to the fullest extent permitted by applicable law, from and against all
Losses, as incurred, to the extent arising out of or based solely upon: (x) such Holder’s
failure to comply with the prospectus delivery requirements of the Securities Act or (y) any
untrue or alleged untrue statement of a material fact contained in any Registration
Statement, any Prospectus, or any form of prospectus, or in any amendment or supplement
thereto or in any preliminary prospectus, or arising out of or relating to any omission or
alleged omission of a material fact required to be stated therein or necessary to make the
statements therein not misleading (i) to the extent, but only to the extent, that such
untrue statement or omission is contained in any information so furnished in writing by such
Holder to the Company specifically for inclusion in the Registration Statement or such
Prospectus or (ii) to the extent that (1) such untrue statements or omissions are based
solely upon information regarding such Holder

-6-

 

furnished in writing to the Company by such Holder expressly for use therein, or to the
extent that such information relates to such Holder or such Holder’s proposed method of
distribution of Registrable Securities and was reviewed and expressly approved in writing by
such Holder expressly for use in the Registration Statement (it being understood that the
Holder has approved Annex A hereto for this purpose), such Prospectus or such form of
Prospectus or in any amendment or supplement thereto or (2) in the case of an occurrence of
an event of the type specified in Section 3(c)(ii)-(v), the use by such Holder of an
outdated or defective Prospectus after the Company has notified such Holder in writing that
the Prospectus is outdated or defective and prior to the receipt by such Holder of the
Advice contemplated in Section 6(d). In no event shall the liability of any selling Holder
hereunder be greater in amount than the dollar amount of the net proceeds received by such
Holder upon the sale of the Registrable Securities giving rise to such indemnification
obligation.

     (c) Conduct of Indemnification Proceedings. If any Proceeding shall be brought
or asserted against any Person entitled to indemnity hereunder (an “Indemnified
Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is
sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have
the right to assume the defense thereof, including the employment of counsel reasonably
satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in
connection with defense thereof; provided, that the failure of any Indemnified Party to give
such notice shall not relieve the Indemnifying Party of its obligations or liabilities
pursuant to this Agreement, except (and only) to the extent that it shall be finally
determined by a court of competent jurisdiction (which determination is not subject to
appeal or further review) that such failure shall have prejudiced the Indemnifying Party.

     An Indemnified Party shall have the right to employ separate counsel in any such
Proceeding and to participate in the defense thereof, but the fees and expenses of such
counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the
Indemnifying Party has agreed in writing to pay such fees and expenses; (2) the Indemnifying
Party shall have failed promptly to assume the defense of such Proceeding and to employ
counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (3) the
named parties to any such Proceeding (including any impleaded parties) include both such
Indemnified Party and the Indemnifying Party, and such Indemnified Party shall reasonably
believe, based upon the opinion of counsel, that a material conflict of interest is likely
to exist if the same counsel were to represent such Indemnified Party and the Indemnifying
Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing
that it elects to employ separate counsel at the expense of the Indemnifying Party, the
Indemnifying Party shall not have the right to assume the defense thereof and the reasonable
fees and expenses of one separate counsel shall be at the expense of the Indemnifying
Party). The Indemnifying Party shall not be liable for any settlement of any such
Proceeding effected without its written consent, which consent shall not be unreasonably
withheld. No Indemnifying Party shall, without the prior written consent of the Indemnified
Party, effect any settlement of any pending Proceeding in respect of which any Indemnified
Party is a party, unless such settlement includes an unconditional release of such
Indemnified Party from all liability on claims that are the subject matter of such
Proceeding.

-7-

 

     Subject to the terms of this Agreement, all reasonable fees and expenses of the
Indemnified Party (including reasonable fees and expenses to the extent incurred in
connection with investigating or preparing to defend such Proceeding in a manner not
inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within
ten Trading Days of written notice thereof to the Indemnifying Party; provided, that
the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of
such fees and expenses applicable to such actions for which such Indemnified Party is not
entitled to indemnification hereunder.

     (d) Contribution. If a claim for indemnification under Section 5(a) or 5(b) is
unavailable to an Indemnified Party (by reason of public policy or otherwise), then each
Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the
amount paid or payable by such Indemnified Party as a result of such Losses, in such
proportion as is appropriate to reflect the relative fault of the Indemnifying Party and
Indemnified Party in connection with the actions, statements or omissions that resulted in
such Losses as well as any other relevant equitable considerations. The relative fault of
such Indemnifying Party and Indemnified Party shall be determined by reference to, among
other things, whether any action in question, including any untrue or alleged untrue
statement of a material fact or omission or alleged omission of a material fact, has been
taken or made by, or relates to information supplied by, such Indemnifying Party or
Indemnified Party, and the parties’ relative intent, knowledge, access to information and
opportunity to correct or prevent such action, statement or omission. The amount paid or
payable by a party as a result of any Losses shall be deemed to include, subject to the
limitations set forth in this Agreement, any reasonable attorneys’ fees or other reasonable
fees or expenses incurred by such party in connection with any Proceeding to the extent such
party would have been indemnified for such fees or expenses if the indemnification provided
for in this Section was available to such party in accordance with its terms.

     The parties hereto agree that it would not be just and equitable if contribution
pursuant to this Section 5(d) were determined by pro rata allocation or by any other method
of allocation that does not take into account the equitable considerations referred to in
the immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d),
no Holder shall be required to contribute, in the aggregate, any amount in excess of the
amount by which the proceeds actually received by such Holder from the sale of the
Registrable Securities subject to the Proceeding exceeds the amount of any damages that such
Holder has otherwise been required to pay by reason of such untrue or alleged untrue
statement or omission or alleged omission, except in the case of fraud by such Holder.

     The indemnity and contribution agreements contained in this Section are in addition to
any liability that the Indemnifying Parties may have to the Indemnified Parties.

     6. Miscellaneous

     (a) Remedies. In the event of a breach by the Company or by a Holder, of any
of its respective obligations under this Agreement, each Holder or the Company, as

-8-

 

the case may be, in addition to being entitled to exercise all rights granted by law
and under this Agreement, including recovery of damages, will be entitled to specific
performance of its rights under this Agreement. The Company and each Holder agree that
monetary damages would not provide adequate compensation for any losses incurred by reason
of a breach by it of any of the provisions of this Agreement and hereby further agrees that,
in the event of any action for specific performance in respect of such breach, it shall
waive the defense that a remedy at law would be adequate.

     (b) No Piggyback on Registrations. Except as set forth on Schedule 6(b)
attached hereto and any securities issued to investors in private placement transactions
effected by the Company after the date of the Purchase Agreement and prior to the actual
filing date of the Registration Statement, neither the Company nor any of its security
holders (other than the Holders in such capacity pursuant hereto) may include securities of
the Company in a Registration Statement other than the Registrable Securities. The Company
shall not file any other registration statement until after the Effective Date, except for
any registration statements filed on Form S-8 under the Securities Act.

     (c) Compliance. Each Holder covenants and agrees that it will comply with the
prospectus delivery requirements of the Securities Act as applicable to it in connection
with sales of Registrable Securities pursuant to the Registration Statement.

     (d) Discontinued Disposition. Each Holder agrees by its acquisition of such
Registrable Securities that, upon receipt of a notice from the Company of the occurrence of
any event of the kind described in Section 3(c), such Holder will forthwith discontinue
disposition of such Registrable Securities under the Registration Statement until such
Holder’s receipt of the copies of the supplemented Prospectus and/or amended Registration
Statement or until it is advised in writing (the “Advice”) by the Company that the
use of the applicable Prospectus may be resumed, and, in either case, has received copies of
any additional or supplemental filings that are incorporated or deemed to be incorporated by
reference in such Prospectus or Registration Statement. The Company will use commercially
reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as it
practicable.

     (e) Piggy-Back Registrations. If at any time during the Effectiveness Period
there is not an effective Registration Statement covering all of the Registrable Securities
and the Company shall determine to prepare and file with the Commission a registration
statement relating to an offering for its own account or the account of others under the
Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as
promulgated under the Securities Act) or their then equivalents relating to equity
securities to be issued solely in connection with any acquisition of any entity or business
or equity securities issuable in connection with the stock option or other employee benefit
plans, then the Company shall send to each Holder a written notice of such determination
and, if within fifteen days after the date of such notice, any such Holder shall so request
in writing, the Company shall include in such registration statement all or any part of such
Registrable Securities such Holder requests to be registered, subject to customary
underwriter cutbacks applicable to all holders of registration rights.

-9-

 

     (f) Amendments and Waivers. The provisions of this Agreement, including the
provisions of this sentence, may not be amended, modified or supplemented, and waivers or
consents to departures from the provisions hereof may not be given, unless the same shall be
in writing and signed by the Company and each Holder of the then outstanding Registrable
Securities; provided, however, that any Holder may waive or consent to departures from the
provisions of this Agreement as long as such waiver or consent does not adversely affect or
impair the rights of the other Holders under this Agreement.

     (g) Notices. Any and all notices or other communications or deliveries
required or permitted to be provided hereunder shall be made in accordance with the
provisions of the Purchase Agreement.

     (h) Successors and Assigns. This Agreement shall inure to the benefit of and
be binding upon the successors and permitted assigns of each of the parties and shall inure
to the benefit of each Holder. Each Holder may assign their respective rights hereunder in
the manner and to the Persons as permitted under the Purchase Agreement.

     (i) Execution and Counterparts. This Agreement may be executed in any number
of counterparts, each of which when so executed shall be deemed to be an original and, all
of which taken together shall constitute one and the same Agreement. In the event that any
signature is delivered by facsimile transmission, such signature shall create a valid
binding obligation of the party executing (or on whose behalf such signature is executed)
the same with the same force and effect as if such facsimile signature were the original
thereof.

     (j) Governing Law. All questions concerning the construction, validity,
enforcement and interpretation of this Agreement shall be determined with the provisions of
the Purchase Agreement.

     (k) Cumulative Remedies. The remedies provided herein are cumulative and not
exclusive of any remedies provided by law.

     (l) Severability. If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or
unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth
herein shall remain in full force and effect and shall in no way be affected, impaired or
invalidated, and the parties hereto shall use their commercially reasonable efforts to find
and employ an alternative means to achieve the same or substantially the same result as that
contemplated by such term, provision, covenant or restriction. It is hereby stipulated and
declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.

     (m) Headings. The headings in this Agreement are for convenience of reference
only and shall not limit or otherwise affect the meaning hereof.

-10-

 

     (n) Independent Nature of Purchasers’ Obligations and Rights. The obligations
of each Holder hereunder are several and not joint with the obligations of any other Holder
hereunder, and no Holder shall be responsible in any way for the performance of the
obligations of any other Holder hereunder. Nothing contained herein or in any other
agreement or document delivered at any closing, and no action taken by any Holder pursuant
hereto or thereto, shall be deemed to constitute the Holders as a partnership, an
association, a joint venture or any other kind of entity, or create a presumption that the
Holders are in any way acting in concert with respect to such obligations or the
transactions contemplated by this Agreement. Each Holder shall be entitled to protect and
enforce its rights, including without limitation the rights arising out of this Agreement,
and it shall not be necessary for any other Holder to be joined as an additional party in
any proceeding for such purpose.

*************************

-11-

 

          IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the
date first written above.

	 	 	 	 	 	 	 
	 	 	ESCALON MEDICAL CORP.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Richard J. DePiano, Jr	 	 
	 

	 	 	 	 

Name: Richard J. DePiano, Jr
	 	 
	 

	 	 	 	Title: President	 	 

[SIGNATURE PAGE OF HOLDERS FOLLOWS]

 

 

[PURCHASER’S SIGNATURE PAGE TO ESMC RRA]

Name of Investing Entity:    Michelle B. White

Signature of Authorized Signatory of Investing Entity:    Michelle B. White

Name of Authorized Signatory:    Michelle B. White

Title of Authorized Signatory:    Owner

[SIGNATURE PAGES CONTINUE]

-13-

 

[PURCHASER’S SIGNATURE PAGE TO ESMC RRA]

Name of Investing Entity:     Lucille D. White Income Only Trust

Signature of Authorized Signatory of Investing Entity:   
Charles E.  White, TTEE

Name of Authorized Signatory:    Charles E.  White

Title of Authorized Signatory:    Trustee

[SIGNATURE PAGES CONTINUE]

-14-

 

[PURCHASER’S SIGNATURE PAGE TO ESMC RRA]

Name of Investing Entity:   Richard J. Snizek Rev Trust

Signature of Authorized Signatory of Investing Entity:   
Richard J. Snizek, TTEE

Name of Authorized Signatory:    Richard J. Snizek

Title of Authorized Signatory:    TTEE

[SIGNATURE PAGES CONTINUE]

-15-

 

[PURCHASER’S SIGNATURE PAGE TO ESMC RRA]

Name of Investing Entity:   James F. Langway

Signature of Authorized Signatory of Investing Entity:   James F. Langway

Name of Authorized Signatory:   James F. Langway

Title of Authorized Signatory:    Owner

[SIGNATURE PAGES CONTINUE]

-16-

 

[PURCHASER’S SIGNATURE PAGE TO ESMC RRA]

Name of Investing Entity:   W. Lincoln Mossop Jr. Trust

Signature of Authorized Signatory of Investing Entity:    W. Lincoln Mossop, Jr.

Name of Authorized Signatory:   W. Lincoln Mossop, Jr.

Title of Authorized Signatory:    Beneficial Owner/Trustee

[SIGNATURE PAGES CONTINUE]

-17-

 

[PURCHASER’S SIGNATURE PAGE TO ESMC RRA]

Name of Investing Entity:   W. Lincoln Mossop III Trust

Signature of Authorized Signatory of Investing Entity:    Wallace L. Mossop, III

Name of Authorized Signatory:   Wallace L. Mossop, III

Title of Authorized Signatory:    Trustee

[SIGNATURE PAGES CONTINUE]

-18-

 

[PURCHASER’S SIGNATURE PAGE TO ESMC RRA]

Name of
Investing Entity:    Wilson & Ellen Saville, JT. TEN.

Signature of Authorized Signatory of Investing Entity:    Ellen M. Saville

Name of Authorized Signatory:   Ellen M. Saville

Title of Authorized Signatory:    Owner

[SIGNATURE PAGES CONTINUE]

-19-

 

[PURCHASER’S SIGNATURE PAGE TO ESMC RRA]

Name of Investing Entity:   Robin Saville Wheeler Living Trust

Signature of Authorized Signatory of Investing Entity:   Robin Saville Wheeler TTEE

Name of Authorized Signatory:    Robin S. Wheeler

Title of Authorized Signatory:    Owner/Trustee

[SIGNATURE PAGES CONTINUE]

-20-

 

ANNEX A

Plan of Distribution

     The selling security holders, which as used herein includes donees, pledgees, transferees or
other successors-in-interest selling shares of common stock or interests in shares of common stock
of Escalon Medical Corp. (“we”, “us” or “our”) received after the date of this prospectus from a
selling security holder as a gift, pledge, partnership distribution or other transfer, may, from
time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or
interests in shares of common stock on any stock exchange, market or trading facility on which the
shares are traded or in private transactions.

     These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at
prices related to the prevailing market price, at varying prices determined at the time of sale, or
at negotiated prices. To the extent any of the selling security holders gift, pledge or otherwise
transfer the shares offered hereby, such transferees may offer and sell the shares from time to
time under this prospectus, provided that this prospectus has been amended under Rule 424(b)(3) or
other applicable provision of the Securities Act to include the name of such transferee in the list
of selling security holders under this prospectus.

     The selling security holders may use any one or more of the following methods when disposing
of shares or interests therein:

	 	•	 	ordinary brokerage transactions and transactions in which the broker-dealer solicits
purchasers;
	 
	 	•	 	block trades in which the broker-dealer will attempt to sell the shares as agent,
but may position and resell a portion of the block as principal to facilitate the
transaction;
	 
	 	•	 	purchases by a broker-dealer as principal and resale by the broker-dealer for its
account;
	 
	 	•	 	an exchange distribution in accordance with the rules of the applicable exchange;
	 
	 	•	 	privately negotiated transactions;
	 
	 	•	 	short sales;
	 
	 	•	 	through the writing or settlement of options or other hedging transactions, whether
through an options exchange or otherwise; broker-dealers may agree with the selling security holders to sell a specified
number of such shares at a stipulated price per share;
	 
	 	•	 	a combination of any such methods of sale; and
	 
	 	•	 	any other method permitted pursuant to applicable law.

-15-

 

     The selling security holders may, from time to time, pledge or grant a security interest in
some or all of the shares of common stock owned by them and, if they default in the performance of
their secured obligations, the pledgees or secured parties may offer and sell the shares of common
stock, from time to time, under this prospectus, or under an amendment to this prospectus under
Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling
security holders to include the pledgee, transferee or other successors in interest as selling
security holders under this prospectus.

     In connection with the sale of our common stock or interests therein, the selling security
holders may enter into hedging transactions with broker-dealers or other financial institutions,
which may in turn engage in short sales of the common stock in the course of hedging the positions
they assume. The selling security holders may also sell shares of our common stock short and
deliver these securities to close out their short positions, or loan or pledge the common stock to
broker-dealers that in turn may sell these securities. The selling security holders may also enter
into option or other transactions with broker-dealers or other financial institutions or the
creation of one or more derivative securities which require the delivery to such broker-dealer or
other financial institution of shares offered by this prospectus, which shares such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended
to reflect such transaction).

     The aggregate proceeds to the selling security holders from the sale of the common stock
offered by them will be the purchase price of the common stock less discounts or commissions, if
any. Each of the selling security holders reserves the right to accept and, together with their
agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to
be made directly or through agents. We will not receive any of the proceeds from this offering.
Upon any exercise of the warrants by payment of cash, however, we will receive the exercise price
of the warrants.

     The selling security holders also may resell all or a portion of the shares in open market
transactions in reliance upon Rule 144 under the Securities Act of 1933, provided that they meet
the criteria and conform to the requirements of that rule.

     Selling security holders who are registered broker-dealers are deemed to be “underwriters”
within the meaning of the Securities Act. In addition, selling security holders who are affiliates
of registered broker-dealers may be deemed to be “underwriters” within the meaning of the
Securities Act if such selling stockholder (i) did not acquire the shares of common stock in the
ordinary course of business or (ii) had any agreement or understanding, directly or indirectly,
with any person to distribute the shares of common stock. In such event, any commissions received
by such broker-dealers or agents and any profit on the resale of the shares purchased by them may
be deemed to be underwriting commissions or discounts under the Securities Act, and such selling
security holders may be subject to certain additional regulations and statutory liabilities under
the Securities Act and Exchange Act. To our knowledge and based upon information we received from
the selling security holders, (i) the selling security holders are not registered broker-dealer or
affiliated with a registered broker-dealer and have acquired the shares of common stock in the
ordinary course of business, (ii) such selling security holders do not have any agreement or
understanding, directly or indirectly, with any person to distribute the shares of common stock,
and (iii) the selling security holders have

-16-

 

not received any securities as underwriting compensation. We are also not aware of any
underwriting plan or agreement, underwriters’ or dealers’ compensation, or passive market making or
stabilizing transactions involving the purchase or distribution of these securities.

     To the extent required, the shares of our common stock to be sold, the names of the selling
security holders, the respective purchase prices and public offering prices, the names of any
agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular
offer will be set forth in an accompanying prospectus supplement or, if appropriate, a
post-effective amendment to the registration statement that includes this prospectus.

     In order to comply with the securities laws of some states, if applicable, the common stock
may be sold in these jurisdictions only through registered or licensed brokers or dealers. In
addition, in some states the common stock may not be sold unless it has been registered or
qualified for sale or an exemption from registration or qualification requirements is available and
is complied with.

     We have advised the selling security holders that the anti-manipulation rules of Regulation M
under the Exchange Act may apply to sales of shares in the market and to the activities of the
selling security holders and their affiliates. In addition, we will make copies of this prospectus
(as it may be supplemented or amended from time to time) available to the selling security holders
for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The
selling security holders may indemnify any broker-dealer that participates in transactions
involving the sale of the shares against certain liabilities, including liabilities arising under
the Securities Act.

     We have agreed to indemnify the selling security holders against liabilities, including
liabilities under the Securities Act and state securities laws, relating to the registration of the
shares offered by this prospectus. The selling security holders have agreed to indemnify us in
certain circumstances against certain liabilities, including liabilities under the Securities Act.

     We have agreed with the selling security holders to keep the registration statement that
includes this prospectus effective until the earlier of (1) such time as all of the shares covered
by this prospectus have been disposed of pursuant to and in accordance with the registration
statement or (2) the date on which the shares may be sold pursuant to Rule 144 of the Securities
Act. We have agreed to pay all expenses in connection with this offering, but not including
underwriting discounts, concessions, commissions or fees of the selling security holders or any
fees and expenses of counsel or other advisors to the selling security holders.

-17-exv10w4

EXHIBIT 10.4

31 December 2008

31 December 2008

BIOCODE-HYCEL FRANCE S.A.

and

BH Holdings

 

AGREEMENT FOR THE SALE OF A

BUSINESS AS A GOING CONCERN

 

 

 

	2	 	Translation
for information.

AGREEMENT FOR THE SALE OF A BUSINESS AS A GOING CONCERN

BETWEEN THE UNDERSIGNED:

	1.	 	Biocode-Hycel France S.A., a company organized under the laws of France having its registered
office at Le Bassin 21320 Pouilly en Auxois, registered with the Trade and Companies Registry
of Beaune under the number 328 517 685, with a share capital of €2,500,000.32, represented by
Mr Roger Duggan, as President General Director, himself duly represented by Mr Alain Rousseau,
duly authorized for the purpose of this Agreement,

Hereinafter referred to as the “Seller”,

AND

	2.	 	BH Holdings, SAS, a company organized under the laws of France having its registered office
at rue de Herhoui, ZI Le Chêne Vert 35650 Le Rheu, registered with the Trade and Companies
Registry of Rennes under the number 509 488 169, with a share capital of €37,000, represented
by Mrs Catherine Bolton, President, herself duly represented by Mrs Sandrine Nicoue, duly
authorized for the purpose of this Agreement,

Hereinafter referred to as the “Purchaser”,

The Purchaser and the Seller being collectively referred to as the “Parties” and individually as a
“Party”,

AND

	3.	 	Escalon Medical Corp., a company organized under the laws of Commonwealth of Pennsylvania
having its registered office at 435 Devon Park Drive, Building 100, Wayne, Pennsylviania
19087, USA, represented by Mr Richard J. De Piano, President, himself duly represented by Mrs
Sandrine Nicoue, duly authorized for the purpose of this Agreement,

Hereinafter referred to as the “Guarantor”,

AND

	4.	 	Immunodiagnostic Systems Holdings Plc, a company organized under the laws of England having
its registered office at 10 Didcot Way, Boldon Business Park, Boldon, Tyne and Wear NE35 9PD,
United Kingdom, registered under the number 05146193, represented by by Mr Alain Rousseau,
duly authorized for the purpose of this Agreement,

Hereinafter referred to as “IDSH”,

AND

	5.	 	Avoxa, société d’exercice libéral à responsabilité limitée, with share capital of
€738,740.00, having its registered office at 5 allée Ermengarde d’Anjou, ZA Atalante Champeaux
CS 40 824 35 108 Rennes cedex 3, registered with the trade and companies registry of Rennes
under number 403 177 637, represented by Mr Florian Bachelier,

Hereinafter referred to as the “Escrow Agent”.

 

 

	3	 	Translation
for information.

RECITALS:

	A.	 	The Seller operates a business as a going concern in Le Rheu and partly in Pouilly-en-Auxois
relating to the development, manufacture and distribution of haematology and flame photometry
instruments and reagents for haematology laboratories and blood banks as further described in
section 2.2 (the “Business”).
	 
	B.	 	The Purchaser has carried out a due diligence of the legal, financial, technical and other
documentation in relation to the Business as provided by Seller, a list of which is attached
in Schedule B (the “Documentation”). Furthermore, an employee of the Purchaser has been
placed with the Seller for the past few weeks preceding the Transfer Date to the date hereof
to meet with the management of the Business to gather financial information and technical
information relating to the description of the Products, as defined hereafter, and their
manufacturing. Pursuant to such due diligence, the Purchaser has confirmed its interest in
purchasing the Business.
	 
	C.	 	The Purchaser desires to purchase from the Seller and the Seller desires to sell to the
Purchaser the Business upon the terms and subject to the conditions set forth in this
agreement (the “Agreement”).

NOW, THEREFORE IT HAS BEEN AGREED AS FOLLOWS:

	1.	 	DEFINITIONS

In addition to such terms defined elsewhere in this Agreement:

“Affiliate” means any entity controlling, controlled by, or under the same control as the Seller
within the meaning of Article L.233-3 of the French Commercial Code.

“Approval Date” means the date on which the labour inspector (inspecteur du travail) will give its
approval for the transfer of the Protected Employees in accordance with Article L. 1224-1 of the
French Labour Code.

“Business ” shall have the meaning set out in section 2.2.

“Contracts” shall mean the agreements listed in Schedule 2.3 entered into by the Seller for the
operation of the Business.

“Copyrights” shall mean the copyrights described in Schedule 2.2.1 (e).

“Damages” shall mean any damages, losses, liabilities, fines, penalties, costs, or expenses
suffered by a Party.

“Domain Name” shall mean the domain name registered with Oleane which can be accessed at the html
address www.biocodehycel.com.

“Employees” shall mean the employees attached to the Business as listed in Schedule 6.6.1.

“Governmental Authority” shall mean any court or other judicial authority or governmental,
administrative or regulatory body, department, agency, commission, authority or instrumentality.

“IDSH Non-compete” shall mean the non-competition and non solicitation agreement subject to English
law entered into at the date hereof between IDSH and the Purchaser.

 

 

	4	 	Translation
for information.

“Intangible Assets” shall mean the intangible assets of the Business set forth in section 2.2.1.

“Intellectual Property” consists in the assets set out in sections 2.2.1 (b) to 2.2.1 (f).

“Know-How” shall mean the know-how described in Schedule 2.2.1 (d).

“Lease” shall mean the lease agreement entered into on 21 September 2005 between the Seller and the
SCI du Chêne Vert located at Chemin de Carnac, l’Albaderaie, 56400 Ploemel for a duration of 9
years from 21 September 2005 until 20 September 2014, for the premises used for the Business
situated at Le Rheu.

“Liability” shall mean any liability, indebtedness, obligation, expense, claim, loss, damage,
deficiency, guaranty or endorsement of or by any person, accrued or unaccrued, due or to become
due, liquidated or unliquidated.

“Material Adverse Effect” means: (1) anything which would substantially prohibit the Purchaser in
producing the Products or selling the Products, or (2) anything that has the effect of causing a
loss or damage to the Purchaser exceeding €10,000.

“Patents” shall mean the Patents described in Schedule 2.2.1 (b).

“Products” means the Instruments and Reagents described in Schedule 2.2.

“Protected Employees” means the protected employees (salariés protégés) listed in Schedule 6.6.4.

“Tangible Assets” shall mean the tangible assets of the Business set forth in section 2.2.2.

“Trademarks” shall mean the trademarks described in Schedule 2.2.1 (c).

“Stock” shall mean the stock of the Products and supplies used for the operation of the Business,
an inventory of which has been carried out by both Parties, as set forth in Schedule 2.2.2 (b).

“Working Day” shall mean any day other than Saturday, Sunday or legal holiday in France, or other
day on which commercial banking institutions in France are required to close.

2. DESCRIPTION AND SALE OF THE BUSINESS

	2.1	 	Sale of the Business
	 
	 	 	The Seller hereby sells, transfers and delivers to the Purchaser, who accepts, the Business
as described in section 2.2 under the terms and conditions hereof.
	 
	2.2	 	Description of the Business
	 
	 	 	With the exclusion of the items set out in section 2.2.3, the Business consists in the
development, manufacture and distribution of the Products, as described in Schedule 2.2, for
haematology laboratories and blood banks and comprises the following assets:
	 
	2.2.1	 	Intangible Assets:

	 	(a)	 	the full clientele attached to the Business and the goodwill;
	 
	 	(b)	 	the Patents as described in Schedule 2.2.1 (b);
	 
	 	(c)	 	the Trademarks as described in Schedule 2.2.1 (c);

 

 

	5	 	Translation
for information.

	 	(d)	 	the Know-How and all trade secrets and non-patented intellectual property as
described in Schedule 2.2.1 (d);
	 
	 	(e)	 	the Copyrights, including computer software and programs, as described in
Schedule 2.2.1 (e);
	 
	 	(f)	 	the Domain Name;
	 
	 	(g)	 	all rights and obligations relating to the assets mentioned above in paragraphs
(a) to (f) and all information, files, records, data, plans and recorded knowledge,
including customer and supplier lists, related to the Business.

	2.2.2	 	Tangible Assets:

	 	(a)	 	equipment and movable assets used for the operation of the Business, listed in
Schedule 2.2.2 (a), and
	 
	 	(b)	 	the Stock as described in Schedule 2.2.2 (b).

	2.2.3	 	Items excluded from the Business:

	 	(a)	 	the after sale services to be provided by the Seller pursuant to the After Sale
Services Agreement as defined hereafter on the territory of France, including the
DOM-TOM, and
	 
	 	(b)	 	the right to the Lease, such Lease being terminated at the date hereof and the
Purchaser entering into a new lease with the landlord of the premises at the date
hereof.

	2.3	 	Transfer of Contracts
	 
	 	 	In addition to the Business, the Seller hereby transfers to the Purchaser the Contracts,
including all customers contracts, equipment leases and other contracts utilized in the
conduct of the Business subject to the agreement of the other contracting parties as
provided under section 5.7.
	 
	2.4	 	Excluded Liabilities
	 
	 	 	The Purchaser shall not be deemed to assume or otherwise be liable for
any liabilities of the Seller or the Business other than as expressly
set forth in this Agreement. The Seller shall retain (and the
Purchaser shall not be obligated for) any and all liabilities of the
Seller of any type that are not expressly assumed by the Purchaser
(the “Excluded Liabilities”).
	 
	3.	 	PROPERTY AND ENJOYMENT
	 
	3.1	 	The Seller declares that it acquired the Business from Hycel further to the merger between
the Seller and Hycel decided by the extraordinary shareholders’ meeting of 24 June 1993.
	 
	3.2	 	The transfer of the full ownership and enjoyment of the Business to the Purchaser, and the
commencement of the use of its attached rights and prerogatives, shall be effective at the
date hereof (the “Transfer Date”).
	 
	4.	 	PRICE AND PAYMENT TERMS
	 
	4.1	 	Purchase Price and Stock Price

 

 

	6	 	Translation
for information.

	4.1.1	 	The sale of the Business, together with the transfer of the Contracts, is made in
consideration of a price of €2,025,949 (the “Purchase Price”) allocated as follows:

	 	(a)	 	Intangible Assets:

	 	(i)	 	Patents: €1,600,000
	 
	 	(ii)	 	All other Intangible Assets other than Patents: €380,427

	 	(b)	 	Tangible Assets with the exception of the Stock: €45,522

	 	 	The above allocation of the Purchase Price is provided for the sole purpose of complying
with Article L. 141-1 of the French Commercial Code but shall not give rise to any liability
from either Party towards the other as regards such allocation notwithstanding any other
valuation from an expert. As the Business is not isolated on the accounting level from the
other activities carried on by the Seller, these financial items result from a good faith
estimate established on the basis of the Business considered separately.
	 
	4.1.2	 	The sale of the Stock is made in consideration of a price of €1,572,051 (the “Stock Price”).
	 
	4.2	 	Payment of the Purchase Price and the Stock Price
	 
	4.2.1	 	The Purchase Price and the Stock Price shall be paid as follows:

	 	(a)	 	€25,000 at the date hereof, such sum to be allocated to the payment of the
Stock Price;
	 
	 	(b)	 	the balance of the Purchase Price and the Stock Price, i.e. an aggregate amount
of €3,573,000 shall be paid in four instalments, under the conditions provided
hereafter, for the following amounts: €198,000 within 18 months from the Transfer
Date, €1,000,000 within 30 months from the Transfer Date, €1,000,000 within 36 months from
the Transfer Date, and €1,375,000 within 48 months from the Transfer Date, such sums
to be allocated first to the payment of the Stock, then of the Tangible Assets and
finally of the Intangible Assets.

	4.2.2	 	Interest

	 	(a)	 	Interest will accrue on the outstanding amount of the Purchase Price and the
Stock Price at an interest rate of 7% per year on the basis of the actual days elapsed
and a 365 day year, as from the Transfer Date.
	 
	 	(b)	 	Accrued interest is payable in arrears by the Purchaser for the first time on
30 November 2009 and continuing thereafter every 6 months, on the last Working Day in
May and November.

	4.2.3	 	Prepayment
	 
	 	 	The Purchaser shall be entitled at any time to prepay in full or in part the balance
outstanding of the Purchase Price and the Stock Price (the principal amount of the Purchase
Price and/or Stock Price being prepaid being hereafter referred to as the “Prepaid Amount”).
Simultaneously upon payment by the Purchaser of any Prepaid Amount, the Purchaser shall pay
to the Seller, in addition to the interest provided under section 4.2.2 (a), the following
prepayment indemnities:

	 	(a)	 	if the Prepaid Amount is paid within 12 months from the Transfer Date, the
Seller shall be entitled to a prepayment indemnity equal to 6% of the Prepaid Amount,

 

 

	7	 	Translation
for information.

	 	(b)	 	if the Prepaid Amount is paid between the 13th and the
24th month from the Transfer Date, the Seller shall be entitled to a
prepayment indemnity equal to 12% of the Prepaid Amount,
	 
	 	(c)	 	if the Prepaid Amount is paid after the 24th month from the Transfer
Date, the Seller shall be entitled to a prepayment indemnity equal to 18% of the
Prepaid Amount.

	 	 	Notwithstanding the above, the Purchase Price and the Stock Price shall in all circumstances
be fully repaid at the latest on the dates provided in section 4.2.1 (b).

	4.2.4	 	Defaults
	 
	 	 	Any outstanding amounts due under this section 4.2 shall become immediately and as of right
payable by the Purchaser in principal, accrued interest and accessory charges, in case one
of the following events occurs (an “Event of Default”):

	 	(a)	 	the Purchaser fails to pay any amount payable by it under this Agreement within
15 days after notice from the Seller that such amount is past due,
	 
	 	(b)	 	in case of any other default by the Purchaser of any of its obligations under
this Agreement which is not remedied within 15 Working Days from notice to this effect
by the Seller,
	 
	 	(c)	 	the Purchaser ceases the operation of the Business, for any reason whatsoever
including, without limitation, the sale of the Business or the dissolution of the
Purchaser;

	 	 	provided that an Event of Default shall not affect the right of the Seller to the additional
amounts to be paid in accordance with section 4.2.3 depending on the date of full payment of
the Purchase Price and Stock Price.

	4.2.5	 	Set off
	 
	 	 	The obligations of the Purchaser under this section 4.2 are unconditional and irrevocable
and cannot be set off against any debt that the Purchaser would hold against the Seller,
unless otherwise stated herein and the Purchaser hereby waives its rights under Articles
1290 to 1299 of the French Civil Code for this purpose.
	 
	4.2.6	 	Guarantee
	 
	 	 	As a guarantee of the full payment of the Purchase Price and the Stock Price:

	 	(a)	 	the Seller shall benefit from the seller’s right granted under Article L. 141-5
of the French Commercial Code on the Business and all the rights and assets relating to
the Business and shall be entitled to the action for rescission (action résolutoire)
provided under Article L. 141-6 of the French Commercial Code, and
	 
	 	(b)	 	the Guarantor grants to the Seller the guarantee as provided under section 13.

	5.	 	CHARGES AND CONDITIONS OF THE SALE OF THE BUSINESS

The present sale is agreed by the Parties under the ordinary and legal charges and conditions,
including the following:

	5.1	 	Condition of the Business

 

 

	8	 	Translation
for information.

	5.1.1	 	The Purchaser purchases the Business in the state in which it is at the Transfer Date,
without being entitled to claim for any indemnity nor any decrease of the Purchase Price for
any reason whatsoever, including latent defects (vices cachés) in accordance with Articles
1641 to 1649 of the French Civil Code, except under the terms and conditions provided under
section 8 and under Article 141-3 of the French Commercial Code in relation to the statements
to be provided pursuant to Article 141-1 of the French Commercial Code.
	 
	5.1.2	 	Subject to anything to the contrary herein, the Seller shall bear all costs and charges
relating to the operation of the Business prior to the Transfer Date and the Purchaser shall
bear all costs and charges relating to the operation of the Business as from the Transfer
Date.
	 
	5.2	 	Accounting books
	 
	5.2.1	 	The Seller and the Purchaser have, in accordance with Article L. 141-2 of the French
Commercial Code, reviewed and signed the monthly statement of turnover from 1st
January 2008 to 30 November 2008, in accordance with Article L. 141-2 of the French Commercial
Code, a signed copy of which is delivered to each Party at the date hereof. However, as the
Business is not isolated on the accounting level from the other activities carried on by the
Seller, the Seller is unable to present the accounting books separately for the Business for
the last three financial years, in accordance with Article L. 141-2 of the French Commercial
Code, and the Purchaser expressly releases the Seller from such obligation.
	 
	5.2.2	 	In accordance with Article L. 141-2 of the French Commercial Code, the Seller shall hold at
the disposal of the Purchaser its accountancy books relating to the Business for a period of
three years as from the Transfer Date.
	 
	5.3	 	Taxes
	 
	 	 	The Purchaser undertakes to pay, as from the Transfer Date, all taxes, all contributions and
other charges of any nature relating to the operation of the Business from and after the
Transfer Date, even in the case where such taxes, contribution and other charges are in the
name of the Seller, it being stated that the amount of business tax (taxe professionnelle)
owed for the year 2008 in connection with the Business shall be paid by the Seller.
	 
	5.4	 	Insurance
	 
	5.4.1	 	The Purchaser shall at its sole discretion carry on or terminate the insurance contracts
listed in Schedule 5.4.1 entered into by the Seller in relation to the operation of the
Business and transferred to the Purchaser as from the Transfer Date in accordance with Article
L. 121-10 of the French Insurance Code.
	 
	5.4.2	 	The Seller shall not be liable for subscribing any insurance policies required to cover, as
from the Transfer Date, any risks resulting from the operation of the Business.
	 
	5.5	 	Employees
	 
	5.5.1	 	All or part of the employment agreements of the Employees shall be transferred to the
Purchaser as stated in Schedule 6.6.1 at the date hereof in accordance with Article L. 1224-1
of the French Labour Code, with the exception of the Protected Employees listed in Schedule
6.6.4 which shall be transferred on the Approval Date.
	 
	5.5.2	 	The Purchaser shall be liable for any obligations entered into with the Employees, for the
part of their employment agreement transferred to the Purchaser as stated in Schedule 6.6.1,
in accordance with the French labour Code, as from the Transfer Date (or from the Approval
Date for the Protected Employees) including, without limitation, for the payment to the

 

 

	9	 	Translation
for information.

	 	 	Employees of their salaries, paid vacation, rights under their employment agreements
(including, if any, any premiums or contributions in kind), which would be accrued and/or
payable as from the Transfer Date (or from the Approval Date for the Protected Employees)
and shall bear all social contributions in relation thereto.
	 
	5.5.3	 	The Seller shall bear for the period ending on the Transfer Date (or the Approval Date, for
Protected Employees), the salaries, paid vacation, rights under the employment agreements of
the Employees (including, if any, any premiums or contributions in kind) and any sums due in
this respect not paid directly to the Employees prior to the Transfer Date (or the Approval
Date, for Protected Employees) and consequently payable by the Purchaser shall be paid by the
Seller upon written demand from the Purchaser.
	 
	5.5.4	 	The Seller agrees with the Purchaser that the Protected Employees, subject to their consent,
shall be made available to the Purchaser by the Seller between the date hereof and the
Approval Date and that the Purchaser shall consequently pay to the Seller in consideration of
such availability the remuneration paid to such Protected Employees and the related social
contributions between the date hereof and the Approval Date.
	 
	5.6	 	Lease
	 
	5.6.1	 	The guarantee deposit granted by the Seller to the landlord under the Lease, i.e. an amount
of €55,000, shall be assigned by the Seller to the Purchaser, such assignment to be notified
by process server to the landlord in accordance with Article 1690 of the French Civil Code.
	 
	5.6.2	 	The Purchaser has agreed to enter into a sub-lease agreement at the date hereof with the
Seller for part of the premises used for the Business in Le Rheu, such sub-lease agreement
being authorised by the landlord as provided under the new lease entered into between the
Seller and the landlord at the date hereof.
	 
	5.6.3	 	The Seller and the Purchaser acknowledge that part of the Business was operated, prior to
the Transfer Date, in the premises owned by the Seller in Pouilly-en-Auxois, but that the
Purchaser shall not maintain any operation of the Business in such premises after the Transfer
Date, unless as otherwise stated in the Transition Manufacturing Agreement.
	 
	5.6.4	 	The Seller and the Purchaser acknowledge that part of the Business was operated, prior to
the Transfer Date, in the premises leased by the Seller in Massy, pursuant to a lease
agreement dated 1st July 1997 and renewed on 8 August 2006 between the Seller and
Société Civile de Placement Immobilier having its registered office at 39 rue de la
Bienfaisance, 75008 Paris for a 9-year period ending on 7 August 2015. As these premises are
mainly used for the activities of the Seller other than the Business, such a lease shall not
be transferred to the Purchaser as a consequence of the sale of the Business. The Seller
agrees, however, to sub-let part of these premises to the Purchaser in accordance with the
sub-letting agreement to be entered into between the Parties upon receipt of the landlord’s
consent.
	 
	5.7	 	Contracts
	 
	5.7.1	 	Transfer of Contracts
	 
	 	 	The Purchaser shall take over the Contracts, including all obligations relating thereto,
with effect from the Transfer Date, except for those contracts in respect of which the other
contracting party’s consent is required and has not been obtained at the date hereof,
provided that:

 

 

	10	 	Translation
for information.

	 	(a)	 	the Seller shall make its best efforts until 1st March 2009 to
obtain the consent from the contracting parties and the Purchaser shall cooperate with
the Seller for this purpose,
	 
	 	(b)	 	until such consent is obtained (or until 1st March 2009, as
appropriate) the Purchaser shall, for its own benefit and to the extent permitted by
the contracts, perform on behalf of the Seller (but at the Purchaser’s expense) all of
the obligations of the Seller arising out of the contracts after the Transfer Date
(including payment obligations),
	 
	 	(c)	 	until such consent is obtained (or until 1st March 2009, as
appropriate) the Seller shall hold any monies, goods or other benefits received under
such contracts for the Purchaser and shall forthwith upon receipt of the same pay or
deliver to the Purchaser such monies, goods and other benefits, and
	 
	 	(d)	 	until such consent is obtained (or until 1st March 2009 as
appropriate) the Seller shall give all reasonable assistance to the Purchaser to enable
it to enforce the rights of the Seller under such contracts in accordance with the
Purchaser’s instructions,
	 
	 	(e)	 	if on 1st March 2009, such consent has not been obtained, the
contracts shall be regarded as not having been transferred to the Purchaser without any
liability from the Seller in connection therewith and the Seller shall be responsible
for carrying on or terminating such contracts with the contracting party at its sole
discretion.

	5.7.2	 	Supply contracts
	 
	 	 	The Contracts and the Business do not include the benefit and charge of supply contracts
relating to water, electricity, telephone, etc. which are not transferred to the Purchaser.
However, the Seller will make its best efforts to assist the Purchaser in obtaining transfer
to it of the telephone numbers used for the Business and listed in Schedule 5.7.2.
	 
	5.8	 	Trade Receivables
	 
	 	 	The Seller owns the trade receivables from its customers listed in
Schedule 5.8 in relation to the Business (the “Trade Receivables”) and
assigns to the Purchaser the Trade Receivables through a separate
receivables assignment agreement which is entered into by the Parties
at the date hereof.
	 
	5.9	 	Work in Progress
	 
	5.9.1	 	Subject to section 5.7 and in consideration of the amount of the Purchase Price, all
contracts and customers’ orders executed but not invoiced and performed in whole or in part by
the Seller prior to the Transfer Date shall be invoiced by the Purchaser and the Purchaser
shall keep the proceeds thereof.
	 
	5.9.2	 	As a result of section 5.9.1, the Seller shall have no liability towards the Business’
customers for the contracts and customers’ orders invoiced by the Purchaser and the Purchaser
shall indemnify and hold harmless the Seller for any loss and expenses incurred by any claim
from a customer against the Seller in relation to such contracts and customers’ orders,
including reasonable legal fees, in accordance with section 8 hereafter.
	 
	5.9.3	 	All costs relating to contracts and customers’ orders executed and performed by the Seller,
in whole or in part, prior to the Transfer Date shall be borne by the Seller and all costs
relating to contracts and customers’ orders executed by the Seller prior to the Transfer Date
and performed by the Purchaser, in whole or in part, after the Transfer Date shall be borne by
the Purchaser.

 

 

	11	 	Translation
for information.

	5.10	 	Other Agreements
	 
	5.10.1	 	The Seller and the Purchaser shall negotiate in good faith and enter into, within 15 Working
Days from the date hereof, a transition manufacturing agreement in relation to the manufacture
of the Instruments, as described in Schedule 2.2 (the “Transition Manufacturing Agreement”),
based on the form of the draft agreement attached hereto in Schedule 5.10.1.
	 
	5.10.2	 	The Seller and the Purchaser shall negotiate in good faith and enter into, within 15 Working
Days from the date hereof, an after sale services agreement in relation to the after sale
services granted to customers having purchased Products prior to the Transfer Date or who will
purchase Products after the Transfer Date (the “After-Sale Services Agreement”), based on the
heads of terms attached hereto in Schedule 5.10.2.
	 
	5.10.3	 	The Seller and the Purchaser shall negotiate in good faith and enter into, within 15 Working
Days from the date hereof, a manufacturing agreement relating to the manufacturing of reagents
for IDS-iSys Analyzer based on the form of the draft agreement attached hereto in Schedule
5.10.3.
	 
	5.11	 	Information Technology
	 
	5.11.1	 	The Purchaser shall grant access to the Seller to the servers transferred to the Purchaser
as part of the Business for a period of three months as from the Transfer Date during normal
working hours, for the purpose of copying all data relating to the activities of the Seller
other than the Business.
	 
	5.11.2	 	The Seller shall bear all expenses in relation to the copying of the data as provided in
section 5.11.1 and shall indemnify and hold the Purchaser harmless in case of any damage
incurred by its access to the Purchaser’s servers for the purpose of section 5.11.1.
	 
	5.12	 	Trade Name
	 
	5.12.1	 	The Seller and the company incorporated under Belgian law, Biocode-Hycel, sell at the date
hereof by separate agreement the Benelux trademark Biocode-Hycel Biotechnology-Diagnostics
No.00981171 filed on 9 January 2001 for the classes 1, 5, 9, 10, 11 et 42 and the
international trademark Biocode-Hycel Biotechnology-Diagnostics filed on 6 July 2001 under No.
765299 for France and Spain for the classes 1, 5, 9, 10,11 et 42, such trademark having been
limited for France to class 5.
	 
	5.12.2	 	The Purchaser hereby authorises the Seller to use “Biocode Hycel” as a trade name and in its
corporate name as “Biocode Hycel France S.A.” for a period of three months after the date
hereof. During the same period, e-mails addressed to the Seller and its employees on the
e-mail accounts biocodehycel.com shall be transferred to a server of the Seller.
	 
	5.13	 	Domain Name
	 
	5.13.1	 	The sale of the Domain Name shall be notified by the Seller to the hosting company of the
Domain Name, Oléane, within 5 Working Days from the date hereof.
	 
	5.13.2	 	The separation of the web sites www.biocodehycel.com and www.idsplc.com shall occur within
10 Working Days from the date hereof and each Party shall cooperate for this purpose.
	 
	5.13.3	 	Notwithstanding the foregoing, the Purchaser undertakes to maintain the sections
“Immunology”, “Biochemistry”, “3x3” or “Biochimie” on the website www.biocodehycel.com and to
set up a link to address all Internet users trying to access these sections to the website of
the Seller www.idsplc.com during a period of 45 Working Days from the date hereof.

 

 

	12	 	Translation
for information.

	5.14	 	Products Declarations
	 
	 	 	The Seller undertakes to provide to the Purchaser within 5 Working Days from the date hereof
the Seller’s complete file with respect to all CE mark declarations relating to the
Products.

	6.	 	REPRESENTATIONS AND WARRANTIES OF SELLER

The Seller hereby make and give to the Purchaser as at the date of this Agreement the
representations and warranties as set forth in this section 6.

	6.1	 	Ownership of the Business
	 
	6.1.1	 	The Seller is the lawful owner of the Business and has full legal right, power and authority
to sell, assign and transfer the Business in accordance with the terms of this Agreement.
	 
	6.1.2	 	The Seller is the owner of the assets and rights comprised in the Business, as described in
section 2.2, and neither such assets and rights nor the Business itself are encumbered by any
real or personal right, easement or security.
	 
	6.1.3	 	The purchased assets described in section 2.2 constitute all of the assets necessary for the
operation of the Business as it is operated at the date hereof, subject to the provisions of
section 5.7.
	 
	6.2	 	Organization, Authority and Enforceability
	 
	 	 	The Seller is a company duly organized and validly existing under the laws of France. The
Seller has the corporate power and authority to enter into this Agreement and to carry out
its obligations hereunder. The entering into this Agreement and the consummation of the
transactions provided for hereby have been authorized by all necessary corporate actions and
proceedings on the part of the Seller.
	 
	6.3	 	Authorizations
	 
	 	 	No prior authorization of any Governmental Authority is required to be made or obtained by
the Seller in connection with the entering into of this Agreement by the Seller, and the
consummation of any of the transactions contemplated by this Agreement.
	 
	6.4	 	Insolvency
	 
	 	 	The Seller is not subject to any proceedings in accordance with the provisions of Book VI of
the French Commercial Code and the Seller is not unable to pay its debts as they fall due
(en cessation de paiement).
	 
	6.5	 	Third party rights
	 
	 	 	There is no registration of any third party rights or pledge or other charges over the
Business at the date hereof in favour of any Governmental Authority or creditor of the
Business, except as indicated in Schedule 6.5.
	 
	6.6	 	Employees
	 
	6.6.1	 	A list of the Employees at the date hereof, with their functions, remuneration and seniority
and setting out the proportion of their employment duties that relate to the Business to be
transferred to the Purchaser is set out in Schedule 6.6.1. Pursuant to Article L. 1224-1 of
the French Labour Code, the employment agreements of the Employees shall be transferred to the
Purchaser at the date hereof (or at the Approval Date for the Protected Employees) in

 

 

	13	 	Translation
for information.

	 	 	proportion to the part of their employment agreement attached to the Business as set out in
Schedule 6.6.1.
	 
	6.6.2	 	The employment agreements of the Employees do not provide for any individual benefit
exceeding those provided by French law, the collective bargaining agreement applicable to the
Business and the Employees, the remuneration (salary and remuneration in kind) of each
Employee indicated in Schedule 6.6.1 or the individual benefits set out in Schedule 6.6.2.
	 
	6.6.3	 	No plan (retirement, health plan, share-profit or other) other than mandatory plans under
French law or the applicable collective bargaining agreement applicable to the Business or the
plans set out in Schedule 6.6.3 is applicable to the Business or the Employees.
	 
	6.6.4	 	The transfer to the Purchaser of the employment agreements of the Protected Employees listed
in Schedule 6.6.4 will be subject to the prior approval of the labour inspector (inspecteur du
travail) after the Transfer Date, in accordance with the provisions of the French Labour Code
and their transfer will take effect on the Approval Date.
	 
	6.6.5	 	The Seller is not a party to, involved in or, to Seller’s knowledge, threatened by, any
labor dispute or unfair labor practice charge relating to the Business, and the Seller has not
experienced any work stoppage by any employees of the Business during the three years
immediately preceding the execution of this Agreement.
	 
	6.7	 	Turnover and profit
	 
	6.7.1	 	The Seller declares that the turnover and the profit or loss before tax resulting from the
Business for the last three financial years and the current year may be assessed as follows:

	 	(a)	 	Turnover:

	 	•	 	From 1st January 2005 to 31 December 2005: K€6,066
	 
	 	•	 	From 1st January 2006 to 31 December 2006: K€5,753
	 
	 	•	 	From 1st January 2007 to 31 December 2007: K€4,763
	 
	 	•	 	From 1st January 2008 to the Transfer Date: K€4,200

	 	(b)	 	Profit or loss before tax:

	 	•	 	From 1st January 2005 to 31 December 2005: profit of K€372
	 
	 	•	 	From 1st January 2006 to 31 December 2006: profit of K€302
	 
	 	•	 	From 1st January 2007 to 31 December 2007: loss of K€75
	 
	 	•	 	From 1st January 2008 to the Transfer Date: loss of K€424

	6.7.2	 	The Business only corresponds to part of the Seller’s activity. The turnover and profit
before tax set out in section 6.7.1 are consequently only assessed for the Seller to comply
with its legal obligations.

	6.8	 	Consents and Approvals
	 
	 	 	Unless otherwise stated herein, neither the execution and delivery by the Seller of the
transaction documents to which it is or will be a party in accordance with this Agreement,
nor

 

 

	14	 	Translation
for information.

	 	 	the performance of the transactions to be performed by the Seller herein, will require any
filing, consent or approval or constitute a default under (a) any regulation or court order
to which Seller is subject, (b) the charter documents, by-laws or other governing documents
of the Seller or (c) any contract, governmental permit or other document to which the Seller
is a party or to which the Business may be subject.
	 
	6.9	 	Certain Personal Property
	 
	 	 	Schedules 2.2.2(a) and 2.2.2(b) describe and specify the location of the items of equipment,
machinery, tools and furniture used exclusively in the manufacture and distribution of the
Products. All of the equipment and movable assets set out in Schedule 2.2.2 (a) are in good
operating condition, subject to reasonable wear and tear.
	 
	6.10	 	Inventory
	 
	 	 	All inventory of the Seller comprised in the Stock consists of items of quality and quantity
saleable in the ordinary course of business at regular sales prices of the Seller. The
inventory records of the Stock established by the Purchaser and the Seller are complete and
accurate with respect to the data contained therein.
	 
	6.11	 	Liabilities
	 
	 	 	None of the purchased assets described in section 2.2 is subject to any Liability, other
than those disclosed in the Documentation or incurred in the ordinary course of business as
from the Transfer Date.
	 
	6.12	 	Legal Proceedings and Compliance with Law
	 
	6.12.1	 	There is no litigation that is pending or, to the Seller’s knowledge, threatened against the
Seller that relates to or could have a Material Adverse Effect on the operations of the
Business or any of the purchased assets as described in section 2.2. There has been no default
with respect to any court order applicable to the Seller which would have a Material Adverse
Effect on the Business.
	 
	6.12.2	 	The Seller has complied in all material respects with all laws, ordinances, regulations and
orders applicable to the Business and the sale of the Products. The Seller has all
governmental licenses and permits material to and necessary in the conduct of the Business as
presently conducted and the sale of the Products, and such licenses and permits are in full
force and effect; no violations are or have been recorded in respect of any such licenses or
permits, and no proceeding is pending or, to the best knowledge of the Seller, threatened to
revoke or limit any such licenses or permits.
	 
	6.12.3	 	All Products are and have been in all material respects in compliance with all applicable
regulations of any governmental agency applicable to such Products. There is no basis known
to the Seller for any governmental agency to deny or rescind any approval or clearance to
market any of the Products for the purpose or indication for which they are being
manufactured, assembled, marketed or sold. To the Seller’s knowledge, there is no action or
proceeding by any governmental agency, including, but not limited to, recall procedures or
withdrawal of clearance to market any Products, pending or threatened against the Seller
relating to the safety or efficacy of any Products.
	 
	6.12.4	 	The Seller has received the regulatory approvals to market the Products in all jurisdictions
where they are currently being marketed.
	 
	6.13	 	Contracts

 

 

	15	 	Translation
for information.

	 	 	To the Seller’s knowledge, the Seller is not in default under any
Contract that could have a Material Adverse Effect the operations of
the Business or any of the purchased assets under section 2.2. The
Seller has not received any communication from, or given any
communication to, any other party indicating that the Seller or such
other party, as the case may be, is in default under any Contract
where such default could have a Material Adverse Effect on the
operation of the Business. This section 6.13 is subject to the
provisions of section 5.7 as regards the transfer of the Contracts to
the Purchaser.
	 
	6.14	 	Patents and Other Intellectual Property
	 
	6.14.1	 	The Seller has exclusive title to, owns, possesses, has the sole right to use or, where
necessary, has made timely and proper application for, the Intellectual Property as necessary
or required to conduct the Business as conducted. All of the Intellectual Property is owned
or otherwise lawfully used by the Seller, and to the Seller’s knowledge, the Seller is not
infringing upon, conflicting with or unlawfully or wrongfully using any patent, trademark,
trade name, service mark, copyright, trade secret or other intellectual property right owned
or claimed by another person. The Seller is not in default, and has not received any notice
of any claim of infringement or any other claim or proceeding, with respect to any such
patent, trademark, trade name, service mark, copyright or trade secret. No current or former
employee of the Seller and, to the Seller’s knowledge, no other person owns any proprietary
right (droit patrimonial) in whole or in part, in any of the Intellectual Property.
	 
	6.14.2	 	The Seller has taken all appropriate measures to protect and preserve the security,
confidentiality and value of its Confidential Information. “Confidential Information” means
those items of the Intellectual Property that are confidential and any other confidential
information owned by Seller, including personnel information, technical information, customer
lists, other customer information and supplier information.
	 
	6.14.3	 	The Seller has all right, title and interest in and to all of the Intellectual Property, and
the same is free and clear of all claims, encumbrances and the like of any nature whatsoever.
The Seller has not granted any licenses to or option on the Intellectual Property and is not
aware of any third parties who are claiming any right, title or interest in or to such
Intellectual Property or who are infringing or violating any of such Intellectual Property.
	 
	6.14.4	 	Except as set forth in Schedule 6.14.4, no royalties, consulting or advisory fees or other
payments are payable by the Seller to any other person by reason of the ownership or use of
the Intellectual Property.
	 
	6.14.5	 	The assignment of the Intellectual Property includes the priority right relating to the
French patent n° 08/02729 filed on 20 May 2008 in the name of the Seller.
	 
	6.14.6	 	The Seller undertakes to fully cooperate with the Purchaser for the filing or recording
procedures with any Patent and Trademark Offices.
	 
	6.15	 	Warranties
	 
	 	 	Set forth in Schedule 6.15 are true and correct copies of all warranties as at 30 November
2008 (a) made by all Persons from whom the Seller has obtained any goods that have been
resold or distributed by the Business, including any goods that constituted parts included
in other goods sold or distributed by the Business and (b) made by the Seller with respect
to any goods that have been sold or distributed by the Seller.

 

 

	16	 	Translation
for information.

	6.16	 	Customers, Distributors and Suppliers
	 
	6.16.1	 	The Seller has used commercially reasonable efforts to maintain, and currently maintains,
good working relationships with all of the customers, distributors and suppliers to the
Business.
	 
	6.16.2	 	Schedule 6.16.2(a) lists any contracts relating to the operation of the Business or any of
the purchased assets with customers or distributors or former customers or distributors of the
Seller that have been terminated or canceled during the one-year period prior to the date
hereof. Schedule 6.16.2(b) also contains a list of the names of each of the major customers of
the Business. None of such customers or distributors has given Seller written notice, or to
the Seller’s knowledge any other notice, terminating, canceling or threatening to terminate or
cancel any contract or relationship with the Seller, and none of such customers or
distributors is, or has been during the one year period immediately preceding the execution of
this Agreement, a related party to the Seller.
	 
	6.16.3	 	Schedule 6.16.3 also contains a list of the names of the major suppliers of components of
and materials used in the manufacture of the Products. Subject to section 5.7, none of such
suppliers has given the Seller written notice, or to the Seller’s knowledge, any other notice,
terminating, canceling or threatening to terminate or cancel any contract or relationship with
the Seller.
	 
	7.	 	REPRESENTATIONS AND WARRANTIES OF THE PURCHASER AND THE GUARANTOR

The Purchaser and the Guarantor hereby represent and warrant to the Seller that, on the date hereof:

	7.1	 	Organization, Authority and Enforceability
	 
	 	 	The Purchaser is a company duly organized and validly existing under the laws of France. The
Guarantor is a company duly organized and validly existing under the laws of Commonwealth of
Pennsylvania (USA). The Purchaser and the Guarantor have the corporate power and authority
to enter into this Agreement and to carry out their obligations hereunder. The entering into
this Agreement and the consummation of the transactions provided for hereby have been
authorized by all necessary corporate actions and proceedings on the part of the Purchaser
and the Guarantor.
	 
	7.2	 	Authorizations
	 
	 	 	No prior authorization of any Governmental Authority is required to be made or obtained by
the Purchaser and the Guarantor in connection with the entering into of this Agreement by
the Purchaser and the Guarantor, and the consummation of any of the transactions
contemplated by this Agreement.
	 
	7.3	 	Insolvency
	 
	 	 	The Purchaser and the Guarantor are not subject to any proceedings in accordance with the
provisions of Book VI of the French Commercial Code or any other similar insolvency
proceedings or receiverships under any applicable law and the Purchaser and the Guarantor
are not unable to pay their debts as they fall due (en cessation de paiement).
	 
	7.4	 	Consents and Approvals
	 
	 	 	Neither the execution and delivery by the Purchaser and the Guarantor of the transaction
documents to which they are or will be a party pursuant to this Agreement, nor the
performance of the transactions to be performed by the Purchaser and the Guarantor herein,

 

 

	17	 	Translation
for information.

	 	 	will require any filing, consent or approval or constitute a default under (a) any
regulation or court order to which the Purchaser and the Guarantor are subject, (b) the
charter documents, by-laws or other governing documents of the Purchaser and the Guarantor
or (c) any contract, governmental permit or other document to which the Purchaser and the
Guarantor are a party.
	 
	8.	 	INDEMNIFICATION
	 
	8.1	 	Indemnification Obligations of the Seller
	 
	 	 	From and after the date hereof and subject to the provisions of this section 8, the Seller
shall indemnify the Purchaser and hold harmless the Purchaser from and against any Damages
actually suffered, paid or required to be paid by the Purchaser as a result of (i) any
inaccuracy or breach of any representation or warranty set forth in section 6, or of (ii)
any breach of any covenant, agreement or other undertaking of the Seller contained in this
Agreement.
	 
	8.2	 	Indemnification Obligations of the Purchaser and the Guarantor
	 
	 	 	From and after the date hereof and subject to the provisions of this section 8, the
Purchaser or the Guarantor shall indemnify and hold harmless the Seller, from and against
any Damages actually suffered, paid or to be paid by the Seller as a direct result of (i)
any material inaccuracy or breach of any representation or warranty set forth in section 7,
or (ii) any material breach of any covenant, agreement or other undertaking of the Purchaser
or the Guarantor contained in this Agreement.
	 
	8.3	 	Method of Asserting Claims, etc.
	 
	 	 	A Party making a claim for indemnification under this section 8 shall, for the purposes of
this Agreement, be referred to as the “Indemnified Party” and the Party or Parties against
whom such claim is asserted under this section 8 shall, for the purposes of this Agreement,
be referred to as the “Indemnifying Party”. All claims by an Indemnified Party shall be
asserted and resolved as follows:
	 
	8.3.1	 	Claim Notices
	 
	 	 	In the event that (x) any claim, demand or proceeding is asserted or instituted by any
Person other than the Parties hereto (including by any Governmental Authority) (a “Third
Party”) which could give rise to Damages for which an Indemnifying Party would be liable to
an Indemnified Party hereunder (any such claim, demand or proceeding, a “Third Party
Claim”), or (y) an Indemnified Party hereunder shall have a claim to be indemnified by any
Indemnifying Party hereunder which does not involve a Third Party Claim (any such claim, a
“Direct Claim”), the Indemnified Party shall send to the Indemnifying Party a written notice
(a “Claim Notice”) of such claim, action or proceeding. A Direct Claim, not involving a
Third Party Claim, may be asserted by a written notice to the Indemnifying Party, which
notice shall set forth in reasonable detail the basis for the Direct Claim, the amount of
the Direct Claim and the basis for the calculation of the amount of the Direct Claim.
	 
	8.3.2	 	Time for Claim Notice
	 
	 	 	The Indemnified Party shall send a Claim Notice: (x) in the case of a Third Party Claim,
within 30 Working Days of receipt of actual notice of such Third Party Claim (or such
shorter period as may be warranted under the circumstances) or within 15 Working Days of
receipt of a notice of a claim if this claim is relating to taxes, (y) in the case of a
Direct Claim, with reasonable promptness in view of the circumstances but in no event later
than 20 Working Days after the Indemnified Party first becomes aware of the facts upon which
the Direct Claim is based. Failure to give notice within the above periods shall prevent the
Indemnified Party to

 

 

	18	 	Translation
for information.

	 	 	ask for indemnification to the Indemnifying Party of the correspondent Direct Claim or Third
Party Claim.
	 
	8.3.3	 	Claim Review Period
	 
	 	 	In the event of a Direct Claim or a Third Party Claim, the Indemnifying Party shall have 20
Working Days following its receipt of the relevant Claim Notice to make such investigation
of the underlying Claim as it considers necessary or desirable. If the relevant parties
agree upon the validity and amount of such Claim, the Indemnifying Party shall pay to the
Indemnified Party, within 10 Working Days following the date of such agreement, the full
agreed amount of such Claim. To the extent that any portion of the Claim is not disputed by
the Indemnifying Party within the period of 20 Working Days, such portion of the Claim shall
be paid by the Indemnifying Parties to the Indemnified Party, ultimately on the last day of
the aforementioned period of 20 Working Days. If the relevant parties are unable to reach
agreement or if the Indemnifying Party disputes its liability to the Indemnified Party in
respect of the underlying Claim, the Indemnified Party shall have the right to commence
legal proceedings against the Indemnifying Party as provided for under section 20.
	 
	8.3.4	 	Defense of Third Party Claim

	 	(i)	 	The Indemnifying Party shall inform the Indemnified Party 20 Working Days from
the receipt of the relevant Claim Notice as to whether the Indemnifying Party elects to
take over at its own costs and expenses the defence of the Third Party Claim and shall
have the right to take over the Third Party Claim if the Indemnifying Party agrees in
writing to be bound by and to promptly pay the full amount of any final judgment from
which no further appeal may be taken. If the Indemnifying Party elects to do so, the
Indemnifying Party shall be considered as having approved the Claim Notice and the
correspondent underlying Damage(s). Notwithstanding the foregoing, the Indemnified
Party shall have the right to join in defense of such claim, action or proceeding at
its own cost and expense.
	 
	 	(ii)	 	If the Indemnifying Party elects to defend a Third Party Claim, the Indemnified
Party shall not be entitled to deal with the claim, and shall refrain from making any
acknowledgement of the claim or conclusion of a settlement or taking an action likely
to jeopardize or interfere with the defence of such Claim. However, the Indemnifying
Party shall, prior to taking any action within the scope of legal proceedings or
otherwise in handling such Third Party Claim, consult with the Indemnified Party and,
in deciding which actions it shall take, the Indemnifying Party shall take into account
the legitimate business interests of the Indemnified Party.
	 
	 	(iii)	 	The Party conducting the defence against a Third Party Claim shall keep the
other Party reasonably informed of any development in the dispute of such Claim and of
its intentions as to how to proceed.
	 
	 	(iv)	 	The Indemnifying Party shall not be liable for any Third Party Claim which is
settled or otherwise compromised or in respect of which any admission of liability is
made without its prior written consent, which consent shall not be unreasonably
withheld or delayed (and which consent shall be deemed to be given if the indemnifying
Party shall not have responded in writing within 20 Working Days of its receipt of a
request for consent by the Indemnified Party). If a settlement offer is received,
which the Indemnifying Party, but not the Indemnified Party, is willing to accept, the
Indemnified Party may elect to continue the defense of such Third Party Claim at its
own expense, in which case the liability of the Indemnifying Party shall be limited to
the lesser of: (i) Damages calculated as if the Third Party Claim were settled in
accordance with the proposed settlement offer; and (ii) the Damages suffered by the

 

 

	19	 	Translation
for information.

	 	 	 	Indemnified Party taking into account the final determination of the Third Party Claim.

	8.3.5	 	Cooperation
	 
	 	 	From and after the delivery of a Claim Notice hereunder, at the reasonable request of the
Indemnifying Party, the Indemnified Party shall grant the Indemnifying Party and its
representatives (including professional advisors) reasonable access to the books, records,
computerized systems, management, employees and properties of the Indemnified Party to the
extent reasonably related to the matters to which the Claim Notice relates. All such access
shall be granted during normal business hours, and shall be granted under conditions, which
will not unduly interfere with the business and operations of the Indemnified Party.
	 
	8.3.6	 	Payment
	 
	 	 	No amount shall become due and payable by the Indemnifying Party to the Indemnified Party in
respect of any Third Party Claim unless and to the extent that the Indemnified Party is
required to pay the relevant Damages to the relevant third party as a result of an
enforceable title or Court decision (titre exécutoire), a decision of an arbitral tribunal
or a binding settlement or other agreement among the relevant parties.
	 
	 	 	In the event that the payment of a relevant Damage is requested by a Third Party and the
amounts required to be paid are not definitive, the Indemnifying Party could, subject to
provide adequate and sufficient guarantees, require the Indemnified Party to ask for payment
delays to the Third Party. If the Indemnified Party does not obtain such delays from the
Third Party, the Indemnifying Party shall be obliged to pay the relevant Damage provided it
will be reimbursed from of all or part of the amount of the Damage by the Indemnified Party
in the event that a definitive decision of a court having jurisdiction finally considers
that all or part said Damage should have not been paid.
	 
	8.4	 	Calculation of Damages
	 
	8.4.1	 	In calculating the amount of any Damages claimed by the Purchaser under section 8, there
shall be deducted:

	 	(i)	 	the amount of any indemnification or other recoveries (including insurance
proceeds) paid to the Purchaser by any third party with respect to such Damages, such
amount to be reduced by the amount of any tax paid or to be paid by the Purchaser in
respect thereof;
	 
	 	(ii)	 	the amount of any corresponding tax savings or benefit (including any tax
reduction, credit, redemption, or loss carry-back or carry-forward) which is or will be
available to the Purchaser in respect of any taxable period in respect of such Damages.

	8.4.2	 	In the event that the amount of any deduction referred to in this section is determined only
after payment by the Indemnifying Party of the amount otherwise required pursuant to this
section, the Indemnified Party shall repay to the Indemnifying Party promptly after such
determination any such payments that the Indemnifying Party would not have had to make
pursuant to this section, had such determination been made at or prior to the time of such
payment.
	 
	8.5	 	Limitations
	 
	 	 	In no event shall the liability of the Seller under this Agreement
exceed the amount of the Purchase Price and the Seller and the Seller
shall be entitled to set off against any amount

 

 

	20	 	Translation
for information.

	 	 	payable in relation to a Claim under this Agreement the amount of any Purchase Price that has not
been paid to the Seller at the date it makes payment to the Purchaser.
	 
	8.6	 	Exclusions
	 
	 	 	The Sellers shall have no liability for Damages which arise as a result of:

	 	(i)	 	actions taken by or on behalf of, or omissions of, the Purchaser after the date
hereof including but not limited to (x) changes in accounting methods or policies, or
(y) the granting of any extensions or waivers with respect to any statute of
limitations applicable to claims which might be made against the Purchaser;
	 
	 	(ii)	 	the passing of, or any change in, after the date hereof, any law or
administrative practice of any Governmental Authority in any such case not actually in
force at the date of this Agreement (even if retroactive in effect), including;
	 
	 	(iii)	 	any information, facts or events disclosed in this Agreement (including its
recitals and Schedules) and in the Documentation.

	8.7	 	Time for Claims
	 
	 	 	Any Claim Notice must be delivered prior to the second anniversary of the date hereof.
	 
	9.	 	FORMALITIES
	 
	9.1	 	Registration and taxes
	 
	9.1.1	 	The Purchaser shall pay the stamp duties and undertakes to register this Agreement with the
tax authorities and return 2 originals duly registered to the Seller within 6 Working Days.
	 
	9.1.2	 	The stamp duties payable by the Purchaser for the acquisition of the Business amount to
€5,310 for the part of the Purchase Price excluding the price of the Patents (i.e. €425,949)
not exceeding €200,000 (i.e. a basis for taxes at the rate of 3% of €177,000), and to €11,297
for the part of the Purchase Price excluding the price of the Patents exceeding €200,000 (i.e.
a basis for taxes at the rate of 5% of €225,949), i.e. a total amount of registration duties
of €16,607.
	 
	9.1.3	 	The price of the Patents, i.e. €1,600,000, is subject to a fixed stamp duty of €125 in
accordance with the Statement Practice No. 7 D-2611 n° 4 dated 15 June 2000, but as the
transfer of the Patents is registered at the same time as the transfer of the Business, no
stamp duty shall be due in this respect.
	 
	9.1.4	 	The Seller and the Purchaser are registered for the purposes of VAT and are legal VAT-liable
taxpayers. It is intended that the Business shall be transferred to the Purchaser as a going
concern and that the provisions of Section 257 bis of the French Tax Code and Statement of
Practice No. 3A-6-06 dated 20 March 2006 shall apply to such transfer and the sale and
purchase of the Business, including the Stock. The parties shall use all reasonable endeavours
to ensure that, by virtue of the provisions of Sections 257 bis of the French Tax Code, no VAT
will be chargeable in respect of the sale and purchase hereby agreed to be made.

 

 

	21	 	Translation
for information.

	9.2	 	Legal publications
	 
	9.2.1	 	The Purchaser shall be responsible for all formalities and publication in relation to this
Agreement, with the exception of the registration pursuant to Articles L. 141-5 and L. 141-6
of the French Commercial Code relating to the Seller’s right granted pursuant to section
4.2.6(a).
	 
	9.2.2	 	Pursuant to Articles L. 141-12 to L. 141-18 of the French Commercial Code, a notice relating
to the present sale shall be published within the time period prescribed by law (fifteen days
following the date of this Agreement), under due care of the Purchaser, in an official gazette
in the département where the Business is operated. The Purchaser shall then apply to the clerk
of the competent commercial court for publication of a notice concerning the transfer in the
Official Bulletin of Civil and Commercial Announcements (Bulletin Officiel des Annonces
Civiles et Commerciales) in the forms and within the time period prescribed by law.
	 
	9.3	 	Registration and removal from the trade and company register
	 
	 	 	Each Party shall, to the extent needed, each as far as it is concerned and under its sole
responsibility, complete the formalities required to register the Business with or remove it
from the Trade and Companies Register within one (1) month following the signature date
hereof, and it alone shall bear their costs.
	 
	9.4	 	Declaration of transfer
	 
	 	 	The Seller undertakes to issue the declaration of transfer of the Business provided for in
Article 201-1 of the French General Tax Code within the 60-day period provided for in the
said Article and to notify the Purchaser that this has been done, at the latter’s first
request. This declaration shall initiate the 3-month period referred to in Article 1684-1 of
the French General Tax Code.
	 
	9.5	 	Patents and Trademarks
	 
	 	 	The transfer of the Patents and Trademarks provided herein shall be filed by the Purchaser,
at its costs and expenses, with the registre national des brevets and the registre national
des marques of the Institut National de la Propriété Industrielle.
	 
	10.	 	ESCROW AND CREDITORS’ RIGHT TO OPPOSITION
	 
	10.1	 	The Parties have agreed to place in escrow with the Escrow Agent the part of the Purchase
Price paid at the date hereof, i.e. €25,000 (the “Escrow Amount”) and the Escrow Agent shall
for this purpose deposit the Escrow Amount with the CARPA.
	 
	10.2	 	The Parties, in their common interest, grant to the Escrow Agent, who accepts, the
irrevocable mandate to:

	 	(a)	 	deliver the Escrow Amount to the Seller once the opposition time periods
expired if all third party claims have been satisfied, or
	 
	 	(b)	 	if claims remain on the Purchase Price, distribute the Escrow Amount amongst
the Seller’s creditors and remit the balance to the Seller.

	10.3	 	The Escrow Agent will be deemed to validly discharge its mission under this section 10 upon
the expiry of the opposition time periods either:

	 	(a)	 	by the delivery to the Seller, the presence or the authorisation of the
Purchaser not being necessary, of the Escrow Amount, or the remaining funds after
payment of the creditors, upon fulfilment of the above conditions, or

 

 

	22	 	Translation
for information.

	 	(b)	 	by the deposit of the Escrow Amount, ordered by the President of the Paris
commercial court, to an escrow agent for the distribution of the Escrow Amount to
creditors or the opening of distribution proceedings.

	10.4	 	All the claims on the Purchase Price shall be made to the registered office of the Escrow
Agent.
	 
	10.5	 	The Escrow Agent agrees not to charge any fees in relation to its mission under this section
10.
	 
	10.6	 	The Seller guarantee the Purchaser that the Seller will deal with any opposition lodged by
any of its creditors in accordance with Article 141-14 of the French Commercial Code at its
costs and expenses and shall indemnify and hold harmless the Purchaser for any costs or
expenses incurred by any such opposition.
	 
	10.7	 	To the extent that the Seller and Purchaser are legally jointly and severally liable for the
payment of any sums owed by the Seller as a result of any opposition validly lodged by any of
the Seller’s creditors, any sums paid by the Purchaser to a creditor of the Seller as a result
of such opposition shall be repaid by the Seller within 5 Working Days upon request from the
Purchaser.
	 
	11.	 	NON-COMPETITION; NON-SOLICITATION
	 
	11.1	 	The Seller, for a period of five years following the Transfer Date, agrees that it shall not,
and shall cause each of its Affiliates, if any, not to, for any reason whatsoever, directly or
indirectly, throughout the world, either individually or as a shareholder, owner, partner,
officer, director, manager, agent, consultant, lender, guarantor or otherwise, engage in, or
have any interest in any other person engaged in the business of developing, manufacturing,
selling or marketing instrumentation and reagents for haematology (haematology being defined,
for the purpose of this section 11.1, as cell blood counting and characterization of white
cells, abnormal and premature cells to detect related pathologies but not including the fields
of coagulation and haemostasis, that is all chemistry, phospholipids, proteins which have a
role in the integrity of blood vessels, in thrombosis and control on fibrinolysis and the
technologies such as but not limited to clotting (clot formation), biochemistry and
immunochemistry utilised to measure parameters in this area), unless as otherwise provided
herein, in the After-Sale Services Agreement or in the Transition Manufacturing Agreement
provided that nothing in this clause 11.1 shall prevent the Seller or its Affiliates from
carrying on any business which is unrelated to business of developing, manufacturing, selling
or marketing instrumentation and reagents in the field of haematology (including for the
avoidance of doubt biochemistry, immunology, coagulation, immunoassay, and haemostasis) or
from continuing to trade in non-haematology products with any customer, client, vendor or
distributor of the Business.
	 
	11.2	 	During the two-year period immediately following the Transfer Date, the Seller agrees that it
shall not, and shall not permit any of its Affiliates to, directly or indirectly, hire, offer
to hire, entice away, retain, employ or solicit or attempt to solicit (either for itself or as
agent for another) for employment or induce, persuade or encourage any person to leave the
employ of the Purchaser or any of its affiliates or subsidiaries who, prior to the Transfer
Date was, or during such two-year period shall be, employed or retained by the Purchaser or
any of its affiliates or subsidiaries as a consultant, agent, employee or otherwise; provided,
however, that this paragraph shall in no way restrict the ability of the Seller or its
affiliates to hire or otherwise contract for the services of any person responding to a
general notice or advertisement for employment or provision of services not specifically
targeted at such person.

 

 

	23	 	Translation
for information.

	11.3	 	The parties acknowledge that the time, scope, geographic area and other provisions of this
Section 11 have been specifically negotiated by sophisticated commercial parties and agree
that all such provisions are reasonable under the circumstances of the transactions
contemplated by this Agreement. Notwithstanding anything in this Section 11 to the contrary,
if at any time, in any judicial proceeding, any of the restrictions stated in this Section 11
are found by a final order of a court of competent jurisdiction to be unreasonable or
otherwise unenforceable under circumstances then existing, the parties agree that the period,
scope or geographical area, as the case may be, shall be reduced to the extent necessary to
enable the court to enforce the restrictions to the maximum extent such provisions are
allowable under applicable law, giving effect to this Agreement and the intent of the parties
that the restrictions contained herein shall be effective to the fullest extent permissible,
and such determination shall not affect the validity or enforceability of the balance hereof,
and such balance shall remain in full force and effect. It is understood that the Seller is
entering into this non-competition agreement in order to induce the Purchaser to enter into
this Agreement.
	 
	12.	 	CONFIDENTIAL INFORMATION
	 
	12.1	 	Except as otherwise required under applicable law or provided herein, in the After-Sale
Services Agreement or in the Transition Manufacturing Agreement, from and after the Transfer
Date, the Seller shall not, and shall not permit any of its Affiliates, if any, to, make use
of, divulge or disclose to any third party (other than the Purchaser or any agent or employee
of the Purchaser) any information of a proprietary, secret or confidential nature related to
the Business.
	 
	12.2	 	This section 12 does not, and will not, restrict the disclosure of any information which (i)
is or becomes available to the public other than as a result of a disclosure by the Seller or
its Affiliates in violation of this Agreement, (ii) becomes available to the Seller or its
Affiliates on a non-confidential basis from a source other than the Purchaser or the Business
which the Seller has no reason to believe to have been obtained directly or indirectly from
any source bound by a confidentiality agreement with or other contractual, legal or fiduciary
obligation of confidentiality to the Purchaser or (iii) is independently developed by or for
the Seller without reference to or reliance upon information obtained in connection with the
operations of the Business, as evidenced by written records.
	 
	13.	 	GUARANTEE FROM GUARANTOR
	 
	13.1	 	The Guarantor irrevocably covenants that it shall be jointly and severally liable for the
Purchaser’s obligations under section 4.2 and the obligations of the Purchaser under the
assignment agreements for the deposit and the Trade Receivables described in sections 5.6.1
and 5.8 (the “Guaranteed Obligations”) and therefore irrevocably undertakes towards the Seller
that until all of the Guaranteed Obligations are fulfilled, to pay to the Seller all sums
payable under the Guaranteed Obligations including (without limitation) any interest,
indemnities, costs and incidentals (including in case of an Event of Default).
	 
	13.2	 	The liability of the Guarantor pursuant to this section 13 shall not be affected by:

	 	(a)	 	any time given to the Purchaser or any failure by the Seller to enforce
compliance of the Purchaser’s obligations; in this respect, the Guarantor waives its
rights under Article 2316 of the French Civil Code;
	 
	 	(b)	 	any variation of the terms of this Agreement or the assignment agreements
described in sections 5.6.1 and 5.8 as may be agreed between the Purchaser and the
Seller;

 

 

	24	 	Translation
for information.

	 	(c)	 	any change in the legal, financial or other condition of the Purchaser
including without limitation any proceedings opened against the Purchaser in accordance
with the provisions of Book VI of the French Commercial Code.

	13.3	 	By undertaking to be liable jointly and severally with the Purchaser, the Guarantor hereby
waives its rights requiring prior proceedings against the principal debtor under Articles 2298
to 2301 of the French Civil Code and its rights to several liability under Article 2303 of the
French Civil Code.
	 
	13.4	 	The Guarantor undertakes that, for so long as all the Guaranteed Obligations are not paid to
the Seller, it shall not exercise any rights or recourse it may have against the Purchaser
(whether by way of subrogation or otherwise, in particular pursuant to Articles 2305 to 2309
of the French Civil Code) nor take any steps resulting in creating competing rights with the
Seller.
	 
	14.	 	GUARANTEE FROM IDSH
	 
	14.1	 	IDSH irrevocably covenants that it shall be jointly and severally liable for the Seller’s
obligations under sections 10.6 and 10.7 and therefore irrevocably undertakes towards the
Seller that until all of the obligations of the Purchaser towards the Seller pursuant to
sections 10.6 and 10.7 are fulfilled, to pay to the Seller all sums payable pursuant to
sections 10.6 and 10.7 including (without limitation) any interest, indemnities, costs and
incidentals.
	 
	14.2	 	The liability of IDSH pursuant to this section 14 shall not be affected by:

	 	(a)	 	any time given to the Seller or any failure by the Purchaser to enforce
compliance of the Seller’s obligations; in this respect, IDSH waives its rights under
Article 2316 of the French Civil Code;
	 
	 	(b)	 	any variation of the terms of this Agreement as may be agreed between the
Purchaser and the Seller;
	 
	 	(c)	 	any change in the legal, financial or other condition of the Seller including
without limitation any proceedings opened against the Seller in accordance with the
provisions of Book VI of the French Commercial Code.

	14.3	 	By undertaking to be liable jointly and severally with the Seller, IDSH hereby waives its
rights requiring prior proceedings against the principal debtor under Articles 2298 to 2301 of
the French Civil Code and its rights to several liability under Article 2303 of the French
Civil Code.
	 
	14.4	 	IDSH undertakes that, for so long as any sums due under sections 10.6 and 10.7 are not paid
to the Purchaser, it shall not exercise any rights or recourse it may have against the Seller
(whether by way of subrogation or otherwise, in particular pursuant to Articles 2305 to 2309
of the French Civil Code) nor take any steps resulting in creating competing rights with the
Purchaser.
	 
	15.	 	ELECTION OF DOMICILE AND NOTICE
	 
	15.1	 	For the purposes of the performance of the Agreement, and for the purposes of the possible
third party oppositions to the payment of the price, the Parties, the Guarantor and IDSH elect
domicile at the addresses indicated in section 15.2.
	 
	15.2	 	All notices and other communications required or permitted to be given or made pursuant to
this Agreement shall be in writing in the French language, together with an English
translation, and shall be: (x) delivered by hand; or (y) sent by an overnight courier service
of

 

 

	25	 	Translation
for information.

	 	 	recognized international standing (all charges paid); or (z) sent by
facsimile transmission before 4:00 p.m. (local time) confirmed by
registered or certified mail (postage prepaid, return receipt requested)
to the relevant Party or the Guarantor or IDSH at its address set forth
below:

	 	 	 	 	 
	 

	 	If to the Seller, to:
	 	Biocode-Hycel France S.A.
	 

	 	 	 	Le Bassin
	 

	 	 	 	21320 Pouilly en Auxois
	 

	 	 	 	France
	 
	 	 	 	 
	 

	 	 	 	Attn: Alain Rousseau
	 
	 	 	 	 
	 

	 	 	 	Fax: + 33 (0)1 64 53 15 12
	 
	 	 	 	 
	 

	 	With copy to:
	 	Immunodiagnostic Systems Holdings Plc
	 

	 	 	 	10 Didcot Way
	 

	 	 	 	Boldon Business Park
	 

	 	 	 	Boldon
	 

	 	 	 	Tyne & Wear NE35 9PD
	 

	 	 	 	United Kingdom
	 
	 	 	 	 
	 

	 	 	 	Attn: Paul Hailes
	 
	 	 	 	 
	 

	 	 	 	Fax: + 44 (0) 191 519 0760
	 
	 	 	 	 
	 

	 	If to the Purchaser, to:
	 	BH Holdings
	 

	 	 	 	Rue de Herhoui
	 

	 	 	 	ZI Le Chêne Vert
	 

	 	 	 	35650 Le Rheu
	 

	 	 	 	France
	 
	 	 	 	 
	 

	 	 	 	Attn : Catherine Bolton
	 
	 	 	 	 
	 

	 	 	 	Fax : + 33 2 99 14 54 52
	 
	 	 	 	 
	 

	 	If to the Guarantor, to:
	 	Escalon Medical Corporation
	 

	 	 	 	Building 100
	 

	 	 	 	435 Devon Park Drive
	 

	 	 	 	Wayne PA 19087
	 

	 	 	 	USA
	 
	 	 	 	 
	 

	 	 	 	Attn: Richard J. DePiano, Sr.
	 
	 	 	 	 
	 

	 	 	 	Fax: 610-688-3641

	 	 	or at such other addresses as hereafter may be provided by either Party or the Guarantor or
IDSH by notice to the other. Any such notice or other communication shall be effective only
upon actual receipt thereof by its intended recipient.

 

 

	26	 	Translation
for information.

	16.	 	EXPENSES

Each Party and the Guarantor will bear their own duties and expenses, including lawyers’,
accountants’ and finders’ fees, with respect to the negotiation, preparation, execution of this
Agreement, as well as the performance of the operations described herein.

	17.	 	DISCHARGE AND SINCERETY
	 
	17.1	 	The Parties discharge, pursuant to this Agreement, entirely and definitively, their
respective legal advisers having drafted this Agreement, who merely transcribed the
declarations freely expressed by the Parties, did not negotiate this Agreement, and were not
responsible for verifying the declarations made by the Parties.
	 
	17.2	 	The legal advisers having drafted this Agreement informed the Parties of the sanctions
applicable in case of price concealment or false affirmations of sincerity, in particular
pursuant to Article 1837 of the French General Tax Code. The Parties confirm that this
Agreement expresses the entirety of the agreed price and that this price has neither been
changed nor contradicted by any collateral agreement increasing the price.
	 
	18.	 	SEVERABILITY

This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or
provision hereof shall not affect the validity or enforceability of this Agreement or of any other
term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or
provision, the Parties hereto and the Guarantor intend that there shall be added as a part of this
Agreement a provision as similar in terms to such invalid or unenforceable provision as may be
possible and be valid and enforceable.

	19.	 	ENTIRE AGREEMENT

This Agreement, including its recitals and schedules, together with the IDSH Non-compete, the
Transition Manufacturing Agreement and the After-Sale Services Agreement represent the entire
agreement and understanding of the Parties and the Guarantor with reference to the transactions set
forth herein and no representations or warranties have been made in connection with this Agreement
other than those expressly set forth herein. This Agreement supersedes all prior negotiations,
discussions, correspondence, communications and agreements between the Parties and the Guarantor
relating to the subject matter of this Agreement.

	20.	 	DISPUTES
	 
	20.1	 	This Agreement shall be governed by and enforced in accordance with the laws of France.
	 
	20.2	 	Any dispute arising out of this Agreement (including, without limitation, any dispute
regarding its validity, performance or termination and any summary proceedings — procédures en
référé — or provisional and protective measures — mesures provisoires ou conservatoires —
notwithstanding any number of defendants, any action on a warranty or guarantee or other third
party proceedings and any counter-claims) shall be submitted to the exclusive jurisdiction of
the Commercial Court of Paris.
	 
	21.	 	WAIVER

Waiver of any term or condition of this Agreement by any party hereto shall only be effective if in
writing and shall not be construed as a waiver of any subsequent breach or failure of the same term
or condition or any other term or condition of this Agreement.

 

 

	27	 	Translation
for information.

	22.	 	BINDING EFFECT; ASSIGNMENT

This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of
the parties hereto and their respective successors and permitted assigns, but neither this
Agreement nor any of the rights, interests or obligations hereunder shall be assigned (whether
voluntarily, involuntarily, by operation of law or otherwise) by any of the parties hereto without
the prior written consent of the other parties; provided that the Seller may not assign any of its
obligations under this Agreement to a third party without the prior written consent of the
Purchaser.

 

 

	28	 	Translation
for information.

Executed in Rennes,

On 31 December 2008,

In 8 signed copies, including one for the registration.

	 	 	 	 	 
	/s/ Alain Rousseau

	 	/s/ Sandrine Nicoue
	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	Seller: Biocode-Hycel France S.A.

	 	Purchaser: BH Holdings	 	 
	 
	 	 	 	 
	Represented by: Mr Roger Duggan,
represented by 

Mr Alain Rousseau

	 	Represented by: Mrs Catherine
Bolton, represented by Mrs Sandrine Nicoue	 	 
	 
	 	 	 	 
	/s/ Sandrine Nicoue

	 	/s/ Alain Rousseau	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	Guarantor: Escalon Medical Corp.

	 	IDSH: Immunodiagnostic Systems Holdings Plc	 	 
	 
	 	 	 	 
	Represented by: Mr Richard J. De
Piano, 
represented by Mrs Sandrine Nicoue

	 	Represented by: Mr Roger Duggan,
represented by Mr Alain Rousseau	 	 
	 
	 	 	 	 
	/s/ Florian Bachelier
	 	 	 	 
	 	 	 	 	 
	Escrow Agent: Avoxa
	 	 	 	 
	 
	 	 	 	 
	Represented by: Mr Florian Bachelier

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00153-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00153-of-00352.parquet"}]]